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Cardiovascular diseases continue to exact unparalleled economic and humanitarian costs 
across the globe.  Manifestations of cardiovascular diseases include acute coronary syndromes 
and heart failure, both of which are exacerbated in diabetic patients. Although the underlying 
cellular culprits responsible for these cardiomyopathies are multi-factorial, aberrant cellular 
bioenergetics is emerging as a central component.  Decrements in mitochondrial function impair 
cardiac function, and accordingly the development of novel therapies that improve cardiac 
function by targeting mitochondria has enormous therapeutic potential. In the work presented 
herein, we studied two diseases where impaired bioenergetics comprises a central component: 
diabetes, and ischemia/reperfusion injury.  In diabetic heart studies, we determined the 
mechanisms responsible for the decline in mitochondrial bioenergetics of the diabetic heart.  
Comprehensive mitochondrial functional assays coupled with molecular techniques were 
employed.  Our results showed that mitochondrial respiration and reactive oxygen species 
buffering capacity were significantly decreased in diabetic hearts. Diabetic mitochondria 
displayed aberrant mitochondrial calcium handling, post-translational oxidative modification of 
the adenine nucleotide translocase, increased sensitivity to permeability transition pore opening, 
and lowered overall expression of proteins involved in the electron transport system. These 
effects led to inefficient energy supply-demand matching and heightened reperfusion injury in 
intact heart studies.  Treatment with several novel therapies that target the mitochondrial inner 
membrane reduced the extent of injury and restored mitochondrial function in the diabetic heart.  
In ischemia/reperfusion studies, we tested the hypothesis that aberrant respiration in the post-
ischemic heart was due to impaired molecular organization along the inner mitochondrial 
membrane.  Specifically, we used a novel respiratory substrate-inhibitor titration protocol to 
determine complex-specific changes, in the electron transport system, that lead to poor 
respiration.  These respiratory studies were coupled with experiments using native gel 
electrophoresis, allowing us to link changes in respiration to altered expression of native 
respiratory “supercomplex” clusters. The decrease in mitochondrial respiration after 
ischemia/reperfusion was observed along several different sites of the electron transport system. 
These changes were associated with lower supercomplex expression, and altered levels of 
several native respiratory complexes.  Post-ischemic treatment with a mitochondria-targeting 
peptide restored supercomplex assembly and was associated with improved respiration and a 
decreased extent of injury. Taken together, the results presented herein provide new insight into 
the molecular and functional alterations that occur along the mitochondrial inner membrane in 
diabetic and post-ischemic hearts. These data provide a basis for novel therapies targeting the 
inner mitochondrial membrane as viable pharmacological approaches to improving bioenergetics 
in diseased myocardium.   
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Chapter 1: Introduction 
Cardiovascular disease  
In the United States, the overall rate of death that was attributed to cardiovascular disease 
(CVD) in 2010 reached 235.5 per 100000 [1]. On this basis, approximately 2150 Americans die 
of CVD each day, averaging 1 death every 40 seconds. Coronary heart disease (CHD) alone 
caused about 1 of every 6 deaths reaching a total of 379559 deaths in 2010 [1]. 
Each year, an estimated 620000 Americans have a new coronary attack and around 
295000 have a recurrent attack. Furthermore, it is estimated that an additional 150000 silent first 
myocardial infarctions occur each year. To put these statistics together, approximately every 34 
seconds 1 American has a coronary event, and approximately every 1 minute 23 seconds an 
American will die of one [1].  
In addition to costing lives, CVD has a big economical impact as well. Indeed, the total 
direct and indirect cost of CVD and stroke reported for 2010 was estimated to be $315.4 billion 
[1]. Therapeutic strategies that diminish the burdens of this disease are a matter of utmost 
importance.  
In order to have an efficient therapeutic approach, key cellular components responsible 
for initiation/complications of CVD need to be identified and targeted. Using IRI and diabetes as 
experimental models, we addressed the structural and molecular changes of critical 
mitochondrial proteins, the impact of these changes on mitochondrial function, and ultimately on 
the cardiac function. We specifically assessed the link between mitochondrial defects and the 
myocardial infarct in diabetic and non-diabetic hearts, as well as mitochondrial defects and 
energy-supply demand mismatching in diabetic hearts.  Lastly, we evaluated the beneficial effect 
of Bendavia in each of our experimental models. Bendavia (also called SS-31 or MTP-131) is a 
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cell-permeable tetra-peptide that targets mitochondria [2]. This peptide has been shown to 
preserve mitochondrial function, to reduce oxidative damage and to protect against cellular death 
following ischemia/reperfusion injury (reviewed in [3]).  This peptide is currently being tested in 
the EMBRACE-STEMI clinical trial for acute coronary syndromes [4].  
Ischemic heart disease  
The American Heart Association defines CHD as the result of plaque buildup in the 
coronary arteries. Overtime, this plaque can chronically limit blood flow to areas of the 
myocardium by narrowing the coronary artery or it can acutely rupture causing a heart attack. 
Areas of myocardium that have limited blood flow, as a result, are said to be ischemic. While re-
establishing blood flow to these areas is essential, it has also been reported to be damaging. The 
damage to the myocardium associated with an ischemia/reperfusion event is referred to as IRI, 
and is identified as the primary cause of sudden cardiac death [5-7].  
During ischemia, oxidative phosphorylation is diminished due to the fall in oxygen 
levels, and this leads to a significant and quick decline in cardiac ATP content. To compensate 
for this energy loss, the myocardium switches to anaerobic metabolism; however, this switch 
leads to a cytosolic acidification. The low pH and aberrant ATP-dependent pump/exchanger 
activities results in a net accumulation of Ca inside the cardiac cell (reviewed in [8]). 
Upon reperfusion, two main events take place leading to the opening of mitochondrial 
PTP and subsequent cellular death. These two events are the high levels of ROS generated 
following the sudden burst in oxygen at reperfusion and the mitochondrial Ca overload that takes 
place following mitochondria repolarization [9-11].  
Interventions that aim at preventing Ca overload by blocking the mitochondrial Ca 
uniporter, along with those that decrease oxidative stress have been shown to be protective 
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against IRI (reviewed in [12]). Results reported in this dissertation (chapters 2 and 3) contribute 
to advancing our knowledge on the regulation of specific mitochondrial proteins involved in 
mitochondria Ca handling and PTP opening. More importantly, these results shed the light on the 
regulation of these proteins in the context of IRI and diabetes and illustrate the clinical potential 
of the mitochondria-targeted peptide Bendavia.  
Ischemic heart disease and diabetes 
Diabetes affects 25.8 million Americans (8.3% of the U.S. population) [13] and 346 
million people worldwide [14]. It is a major cause of heart disease and stroke. In fact, death rates 
from heart disease and the risk of stroke are about 2 to 4 times higher among adults with diabetes 
than among those without diabetes [13]. This increased cardiac mortality rate is independent of 
both coronary artery disease and hypertension [15], suggesting an underlying defect at the level 
of the cardiomyocyte [16]. 
Among the myriad factors involved in the increased cardiac mortality rate in diabetic 
patients, recent evidence suggests that decrements in bioenergetics coordination are centrally 
involved. While the healthy heart is proficient at adjusting its mitochondrial ATP production to 
changing workloads, the diabetic heart has a very limited capacity of energy matching [17, 18]. 
A growing body of literature indicates that alterations in mitochondrial function may be 
responsible for the increased cardiac dysfunction observed in diabetes (reviewed in [19]).  
Diabetic hearts also exhibit oxidative stress characterized by an increase in ROS 
production [20, 21] and a decreased capacity to buffer them [22-24]. We believe that a direct 
consequence of this oxidative shift in cellular redox environment is an oxidative modification of 
key mitochondrial protein complexes that eventually lead to either their degradation or 
dysfunction.   
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Calcium plays a key role in both the optimal function and dysfunction of the 
mitochondria. Physiological levels of mitochondrial Ca are vital for ATP generation which is 
crucial for cardiac function, but Ca overload leads to mitochondrial dysfunction and cellular 
death. For this reasons, mitochondrial Ca uptake and the nature/identity of the mitochondrial Ca 
uniporter have been the subject of multiple investigations over the last 50 years. Understanding 
how mitochondrial Ca uptake is regulated in health and disease can help us better understand the 
contribution of mitochondrial Ca to the cardiac energy supply-demand matching under 
physiological and pathological conditions. 
To address the changes that might impact mitochondrial Ca uptake in the diabetic heart, 
we looked at the molecular alterations of mitochondria in healthy and diabetic hearts. More 
specifically, we measured the levels of mitochondrial Ca handling proteins and evaluated the link 
between these levels and the overall mitochondrial function (chapter 3). The goal was to advance 
our understanding of the mechanisms responsible for the known impaired cardiac mitochondrial 
Ca dynamics in diabetes. We accomplished that by identifying and measuring the molecular 
changes of key proteins that are directly or indirectly involved in ATP generation (chapter 3).  
The role of mitochondria in cardiac function  
The main function of mitochondria is ATP synthesis via oxidative phosphorylation. After 
substrate oxidation, reducing equivalents generated by the tricarboxylic acid cycle are used by 
the electron transport chain (ETC) to generate the mitochondrial membrane potential that drives 
ATP synthesis [25]. For the heart, this ATP synthesis is crucial to its main function which is to 
continuously supply the whole body with oxygen and nutrients. This task requires the heart to 
match its energy supply to demand on a beat-to-beat basis, and this is reflected by the important 
mass of cardiac mitochondria, as it occupies 35% of the cardiac cell volume [26]. As an example 
of the constant energy matching, a 7-fold increase in cardiac output results in a 10-fold increase 
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in myocardial oxygen consumption. The latter is a direct index of ATP consumption by the heart 
[27]. So, constantly matching cardiac ATP supply to demand is critical to ensure sufficient fuel 
availability for the heart to perform its function. Therefore, a constant communication between 
the cytosol (compartment of energy consumption) and the mitochondria (compartment of energy 
generation) is essential.  
Two mechanisms have been proposed as possible regulators of this communication 
between the cytosol and mitochondria and the ultimate regulation of ATP synthesis. First, the 
levels of adenosine di-phosphate (ADP) and inorganic phosphate (Pi) because an increase in 
ATP utilization in the cytosol leads to an increase in ADP and Pi fluxes to mitochondria, and a 
concomitant increase in the amount of available substrates for ATP production. Second, free 
cytosolic Ca concentration because it is coupled with 1) ATP utilization by the contracting 
cardiac muscle, 2) mitochondrial Ca fluxes, and 3) Ca-dependant activation of mitochondrial 
enzymes involved in ATP production (reviewed in [28]). In the work presented here we looked 
at the molecular control of mitochondrial Ca fluxes in relation to cardiac bioenergetics (chapter 
3).  
A new paradigm for optimal mitochondrial function has recently emerged. It is the 
structural organization of the mitochondrial respiratory complexes (MRCs) into supramolecular 
configuration called supercomplexes. When the MRCs are organized as such, electron transfer 
through partner redox components is more efficient [29], and electron loss that leads to ROS 
formation is minimal [30]. This electron transfer efficiency might result in an optimal energy 
production, especially that the organization of these supercomplexes is said to be dependent and 
regulated by the type of substrate used [31].  
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The mitochondrial respiratory complexes  
The ETC is composed of five multi-subunit complexes: NADH-ubiquinone 
oxidoreductase (commonly known as complex I), succinate-ubiquinone oxidoreductase (complex 
II), ubiquinol-cytochrome c oxidoreductase (cytochrome bc1 complex or complex III), 
cytochrome c-O2 oxidoreductase (complex IV), and F1Fo-ATP synthase (complex V), in 
addition to 2 mobile electron carriers, ubiquinone and cytochrome c [25]. Complexes I and II are 
the two major routes of entry of electrons into the ETC. The electrons are then transferred 
through a series of redox centers in complex III and IV until reaching the molecular oxygen 
which is the last electron acceptor. Complexes I, III and IV couple electron transfer with the 
pumping of protons from the mitochondrial matrix into the intermembrane space thus, generating 
a proton gradient across the inner mitochondrial membrane. Complex V utilizes the potential 
energy stored in this proton gradient to regenerate ATP [32]. 
Structural organization of the mitochondrial respiratory complexes  
The structural and functional organization of the MRCs has been subject of multiples 
investigations since they were successfully purified from bovine heart mitochondria in 1962 
[33].  Currently, there is evidence for 2 models describing the organization of MRCs; the fluid-
state model and the solid-state model. 
Fluid-state model 
In this model, the respiratory complexes are described as free units that are randomly 
dispersed and able to move by lateral diffusion through the lipid bilayer [34]. Electron transfer is 
facilitated by the movement of ubiquinone, transferring electrons from complex I/II to complex 
III, and cytochrome c, transferring electrons from complex III to IV. This model is the most 
described in the literature and is widely accepted. 
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Solid-state model 
The observation that the MRCs are not present in a stoichiometry of one-to-one, brought 
Hochman et al. to propose a “dynamic aggregate model” in which the components of the ETC 
exist as complete aggregates, partial aggregates and freely diffusing components, all active in 
electron transfer [35]. In this model, electron transfer can occur by random diffusion, but higher 
rates are achieved by formation of transitory complexes between appropriate redox partners.  
This dynamic aggregate model hypothesis was the first statement in favor of the 
existence of a supramolecular organization of the MRCs. Hochman et al. described the function 
of these dynamic aggregates as follows: “In so far as such associated forms exist, the efficiency 
of electron transfer will increase and overall rates will be observed that are faster than those 
predicted by a totally random diffusion process. A corollary of the hypothesis is that changes in 
the stability or lifetime of aggregated forms may provide a mechanism of regulation, in addition 
to normal respiratory control” [35]. 
Today, evidence based on the separation of MRCs by blue native-polyacrylamide gel 
electrophoresis (BN-PAGE), suggests that the respiratory complexes I, III, and IV can associate 
in different stoichiometries to form supramolecular assemblies with functional features, called 
supercomplexes or respirasomes [31, 36-38]. As illustrated in Figure 1, these organizations 
promote optimal vicinity between different complexes and result in a more efficient electron 
transfer from one complex to the other thus, improving mitochondrial function [29] and 
decreasing electron loss and ROS generation [30, 31]. Besides the BN-PAGE analysis, 
supercomplexes structure was also confirmed by electron microscopy analysis [39], cryoelectron 
microscopy [40], and single particle analysis [40, 41]. 
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Cardiolipin and the mitochondrial function 
Cardiolipin is a phospholipid found mostly in the inner mitochondrial membrane where it 
represents around 30% of the total lipid content (reviewed in [42]).  This phospholipid is 
essential for the optimal structure, stability and activity of multiple MRCs including comlexes I 
and V (reviewed in [42]). Cardiolipin is also critical for the organization of MRCs into 
respirasomes since it helps hold the different complexes together [43]. Cardiolipin peroxidation 
and/or loss were reported and linked to mitochondrial dysfunction under different disease states 
including ischemia/reperfusion injury and heart failure (reviewed in [42]). Recent evidence 
shows that Bendavia might exert its protective action by targeting cardiolipin [44].  
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Figure 1:  Organization of the mitochondrial respiratory complexes into free complexes or 
supercomplexes (respirasomes). From [45] with permission (see Appendix B). Respirasomes are 
formed by the assembly of respiratory complexes I, III and IV in different stoichiometries.   
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Calcium and cardiac bioenergetics 
The heart is capable of sustaining adequate cardiac function with changing metabolic 
demand by continuously balancing the rate of mitochondrial ATP production with utilization. Ca 
initiates and powers muscle contraction which makes it an ideal feed-forward signal for priming 
ATP production. In fact, Ca plays a key role in the cardiac constant phosphorylation potential 
because it signals the cytosolic needs in ATP to the energy generating machinery of the 
mitochondria [46, 47].  
For a long time mitochondria was considered to play a role in Ca buffering during 
diastole; however, it is now clear that mitochondrial Ca uptake is essential to matching energy 
supply to demand. Once inside the mitochondrial matrix, Ca actively stimulate several 
dehydrogenases of the Krebs Cycle as well as ANT, and the F1/Fo ATP-synthase [46-51]. The 
activity of these proteins is essential for ATP synthesis and delivery to the contractile machinery.  
Mitochondrial Ca influx occurs primarily via the mitochondrial Ca uniporter (MCU), an 
ion channel within the inner mitochondrial membrane whose molecular identity has recently 
been elucidated [52, 53]. The activity of MCU is regulated by at least 2 newly characterized 
mitochondrial proteins: Mitochondrial Ca uptake 1 (MICU1) [54] and mitochondrial Ca uptake 
regulator 1 (MCUR1) [55], and its physiological role in mitochondrial Ca uptake, as well as the 
consequent energy supply-demand matching has recently been further confirmed [56]. By using 
a transgenic mouse lacking MCU, Pan and Colleagues showed that in the absence of MCU, the 
animals lose the ability to rapidly uptake Ca, and exhibit alterations in the phosphorylating 
activity of pyruvate dehydrogenase [56]. 
While it is well known that mitochondrial Ca influx is decreased in the diabetic heart [57-
59], there are no data linking this decrease to changes in activity/expression of Ca-handling 
11 
 
proteins/channels.  Further, whether these proteins can be regulated by a therapeutic intervention 
is not known. In chapter 3, we address those questions in diabetic and non-diabetic hearts.  
Conclusion and central hypothesis 
Heart disease is the leading cause of death for both men and women  
[60] and several medical conditions can put individuals at higher risk for this disease. Diabetes is 
a major risk factor as well as a complicating condition for heart disease. Indeed, diabetic patients 
are more vulnerable to this disease, and have lower rate of recovery from myocardial ischemic 
events. The underlying pathological factors of the diabetic state, such as the high oxidative 
burden, the poor handling of Ca, and the energetic inefficiency all contribute to the increased 
susceptibility of diabetic patients to IRI. Multiple investigations have identified mitochondria as 
the culprit in both IRI and diabetes, and proposed some therapeutic approaches that would 
reverse/diminish the mitochondrial dysfunction. However, we are still awaiting drug/drugs that 
will have an application in the clinic, will reach the mitochondrial target/targets, and improve the 
recovery of cardiac function after an ischemic event. The fact that therapies such as antioxidants 
have not been successful in the clinical setting [61] is an indicator of our limited understanding 
of all the molecular and structural changes that take place in the mitochondria under diabetic and 
ischemic conditions. The working premise of this dissertation is that diabetes and IRI overwhelm 
the intrinsic mitochondrial antioxidant capacity, and result in an oxidative shift of the cellular 
redox state. This shift can lead to oxidative modifications of key mitochondrial proteins as well 
as the environment surrounding these proteins, and result in declined mitochondrial 
bioenergetics.  We propose to identify the molecular and structural modifications taking place at 
the level of the inner mitochondrial membrane, under two diseased states: IRI and diabetes. We 
hypothesize that: 1) the increased susceptibility of diabetic hearts to IRI is due to an increased 
sensitivity to PTP opening, 2) the cardiac inefficiency of diabetic hearts is, at least in part, due to 
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alterations of mitochondrial Ca handling proteins as well as an overall declined mitochondrial 
function and 3) the mitochondrial dysfunction in the post-ischemic heart is due to impaired 
molecular organization along the inner mitochondrial membrane.  
By using a mitochondria-targeting peptide that has been shown to be protective against 
mitochondrial dysfunction in different cardiac diseases, we hope to pinpoint its main 
mitochondrial target/targets and to better understand the changes that take place in the 
mitochondria of diabetic and ischemic hearts.  
  
 
 
Chapter 2: Mitochondrial permeability transition in the diabetic heart: Contributions of 
thiol redox state and mitochondrial calcium to augmented reperfusion injury. 
From: Ruben C. Sloan, Fatiha Moukdar, Chad R. Frasier, Hetal D. Patel, Phillip A. Bostian, 
Robert M. Lust, David A. Brown. Journal of Molecular and Cellular Cardiology, 52 (2012): 
1009–1018 (http://dx.doi.org/10.1016/j.yjmcc.2012.02.009) [62]  
 
Introduction 
The global population of diabetics is estimated to reach 300 million by the year 2025 
[63]. Among the myriad complications associated with diabetes mellitus, diabetics have a higher 
mortality rate following myocardial infarction [64], with hyperglycemia independently 
increasing the mortality risk [65]. Animal models of diabetes indicate increased 
ischemia/reperfusion injury in diabetic hearts [66-68], but the underlying mechanisms 
responsible for augmented injury in diabetic hearts are not fully understood. Insight into the 
cellular pathways involved in diabetic ischemic injury has potential to foster novel therapeutic 
strategies seeking to diminish ischemic injury in the rapidly growing diabetic population. 
While the etiology of ischemia/reperfusion injury is undoubtedly multi-factorial [8], a 
growing body of evidence suggests that opening of the mitochondrial permeability transition 
pore (PTP) is involved (reviewed in [19]). Diabetic heart mitochondria demonstrate an enhanced 
susceptibility to PTP opening in both humans [66] and animal models of diabetes [69-71], but 
the mechanisms contributing to augmented PTP opening in diabetes are not known. Studies in 
non diabetic animals have demonstrated that PTP opening is favored when mitochondrial levels 
of ROS and calcium are high [9, 72-75]. Increased mitochondrial ROS production ultimately 
leads to oxidation of protein thiols associated with the PTP, which is known to increase PTP 
calcium sensitivity [76]. 
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Given that diabetic heart mitochondria exhibit impaired ROS scavenging [22, 23, 77], 
particularly by the glutathione redox couple [68, 78, 79], we hypothesized that the enhanced PTP 
opening in diabetic mitochondria is secondary to oxidative shifts in the cellular redox 
environment. We hypothesized that modifying the thiol redox state in isolated mitochondria with 
the thiol reductant dithiothreitol would delay PTP opening in diabetic mitochondria. Further, we 
speculated that reducing the oxidant burden in vivo with a novel mitochondria targeted peptide 
(MTP-131, an analog of SS-02 and SS-31; [3, 80]) would also attenuate the PTP open 
probability in diabetic heart mitochondria. This cell-permeable peptide has been shown to 
decrease intracellular ROS levels and reduce mitochondrial depolarization in a number of cell 
types undergoing oxidative stress [80].  
To determine if these approaches in mitochondria translate to tissue salvage in the intact 
hearts, we hypothesized that three different pharmacological approaches administered at the 
onset of reperfusion would protect tissue by keeping PTP closed. We used NIM811, a non-
immunosuppressive analog of cyclosporin-A to block the PTP [81], minocycline to block 
mitochondrial calcium influx [82], and MTP-131 to reduce mitochondrial ROS production 
during reperfusion. 
Methods 
Experimental animals 
All animal procedures received prior approval by the East Carolina University 
Institutional Animal Care and Use Committee. Male Sprague–Dawley rats (7–9 weeks old) were 
housed in a temperature (22°C) and light-controlled (12 hour light/12 hour dark) environment 
and fed standard rat chow (Research Diets, New Brunswick, NJ, USA) and water ad libitum.   
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After at least 5 days of acclimation to the facility, diabetes was induced with a single 
intraperitoneal (i.p.) injection of streptozotocin (STZ, 65 mg/kg) dissolved in 100 mM sodium 
citrate (pH=4.5) following a 12-hour overnight fast. Control animals received an i.p. injection of 
sodium citrate. All experiments were performed 2 weeks following STZ injection. Blood glucose 
was determined from tail vein samples using a commercially available glucometer (One Touch 
Ultra 2, LifeScan, Milpitas, CA, USA). Plasma non-esterified fatty acids were measured using a 
commercial kit (#SFA-1, Zen-Bio, RTP, NC), based on the method described by Johnson and 
Peters [83] and following the manufacturer's instructions.  
On the day of experimentation, rats were anesthetized with a ketamine/xylazine cocktail 
(90 mg/kg and 10 mg/kg, respectively; i.p. injection) and hearts were removed via bilateral 
thoracotomy. Once excised, hearts were used in one of three major study arms: 1. Left 
ventricular glutathione content and immunoprecipitation/western blot experiments for ANT 
redox state, 2. Experiments in isolated mitochondria, or 3. Ex vivo Ischemia/Reperfusion. 
Myocardial glutathione 
Left ventricles from a subset of control and diabetic animals (n=5 rats in each group) 
were excised and frozen for subsequent assays to determine myocardial glutathione content. 
Total glutathione, oxidized glutathione (GSSG), reduced to oxidized glutathione ratio 
(GSH/GSSG), glutathione reductase, and glutathione peroxidase were determined using our 
established protocols [84]. 
ANT Western blots and thiol redox state assay 
Aliquots of LV mitochondria proteins were solubilized, subjected to SDS-PAGE and 
transferred to an Immobilon-P transfer membrane. After blocking in Tris-buffered saline 
containing 0.1% Tween (TBS-T) and 4% bovine serum albumin for 1 h at room temperature, the 
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membrane was incubated with the ANT antibody (1:1000; Santa Cruz) overnight at 4 °C. The 
membrane was washed with TBS-T and incubated with an IR-Dye-conjugated secondary 
antibody for 1 h at RT then washed again with TBS-T and finally with TBS. The 
immunoreactive bands were scanned and quantified using the Odyssey Infrared Imaging system 
and software, respectively (Li-COR Biosciences, Lincoln, NB). 
Free reactive thiol (SH) groups on the adenine nucleotide translocase (ANT) were labeled 
using IR-Dye 800CW-Maleimide (Li-COR Biosciences) by a modification of the technique 
described by Riederer et al. [85]. This approach allows maleimide groups to react with sulfhydryl 
groups of proteins at pH 6.5–7.5 and form a stable thioether bond. Samples of LV were 
homogenized in buffer (0.1 M Na2HPO4, and 0.15 M NaCl, pH 7.5) containing protease inhibitor 
cocktail and 100 nM IRDye 800CW-Maleimide. The labeled proteins in the supernatant were 
obtained by centrifugation at 14,000 rpm for 10 min. Excess free IR-Dye 800CW-Maleimide 
was removed over Zeba columns (Pierce) and protein concentration was determined using BCA 
kit (Pierce). 500 μg labeled proteins were incubated with 2 μg of the ANT antibody and 40 μL of 
Protein G PLUS-Agarose beads slurry (Santa Cruz), overnight at 4 °C on a rotating platform. 
The bound proteins were eluted with Laemmli loading buffer and underwent SDS-PAGE. The 
gels were scanned and quantified using the Odyssey imaging system and software, respectively. 
To validate the effectiveness of the method to detect ANT thiol redox state, 2.5 mg 
proteins were incubated with either 5 mM H2O2 or 5 mM DTT for 30 min at RT on a rotating 
platform. The excess DTT and H2O2 were removed over Zeba columns and the final protein 
concentration was determined using the BCA kit. The proteins were then subjected to maleimide 
labeling and underwent SDS-PAGE as described above. 
Mitochondrial isolation 
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Cardiac mitochondria were isolated from the left ventricle of hearts utilizing a protocol 
similar to Boehm et al. [86]. For the mitochondrial isolation, all steps were performed at 4°C, 
and all instruments for the procedure were chilled overnight prior to the isolation at 4°C. Hearts 
were excised and immersed in 10 mL ice-cold isolation solution (IS) containing (in mM): 300 
sucrose, 10 sodium-hepes and 0.2 EDTA. The left ventricle was isolated, weighed, and rinsed in 
fresh IS buffer. Hearts were minced into 2–3 cm3 cubes and subjected to 2 min of digestion using 
1.25 mg trypsin, diluted in 10 mL of IS (pH=7.2). Following digestion, 6.5 mg of trypsin 
inhibitor was added, diluted in 10 mL IS buffer+BSA (1 mg/mL) at pH=7.4. Tissue was 
resuspended in 10 mL IS buffer+BSA and homogenized with a teflon Potter homogenizer. The 
homogenate was centrifuged at 600 g for 10 min, and the supernatant was then centrifuged at 
8000 g for 15 min. The supernatant was discarded, and the pellet re-suspended in 10 mL IS 
buffer+BSA. This step was repeated one more time, and the final pellet was stored on ice in 
~150 μL IS buffer. Mitochondrial protein content was determined using a BCA protein assay. 
Determination of respiratory control ratio 
To determine the quality of our mitochondrial preparations, mitochondrial rates of 
respiration were measured using a Clark-type micro-oxygen electrode (Microelectrodes, 
Bedford, NH, USA). Reactions were conducted in a closed, magnetically stirred chamber in 2.5 
mL mitochondria assay buffer containing (in mM): 125 KCl, 5 HEPES, 2 KH2PO4, 1 MgCl2 and 
0.5 mg mitochondria (25°C, pH=7.3). Following a two-minute equilibration period, 
mitochondria were energized with 5 mM glutamate/5 mM malate to initiate state 2 respiration. 
State 3 respiration was initiated with the addition of 2.5 mM ADP. Respiratory control ratios 
were calculated by dividing the state 3 respiration by the state 2 respiration. 
Calcium retention capacity 
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Mitochondria (0.75 mg) were suspended in mitochondria assay buffer (described in 
section 2.3) and supplemented with the fluorescent probe 1 μM calcium green 5 N salt to track 
changes in extramitochondrial calcium. Extramitochondrial calcium fluorescence was measured 
using a fluorescence spectrophotometer (Photon Technology International, Birmingham, NJ, 
USA), with excitation and emission wavelengths set to 506/532 nm, respectively. Calcium-
induced PTP opening experiments were performed under state 2 conditions (5 mM glutamate/5 
mM malate). Mitochondrial PTP opening was induced by subjecting mitochondria to serial 50 
nmol CaCl2 pulses at 3-minute intervals. PTP induction was denoted by the inability of 
mitochondria to take up calcium (reflected by a sharp increase in extramitochondrial calcium 
fluorescence). Calcium retention capacity was quantified as the amount of calcium needed to 
induce PTP opening (nmol CaCl2/mg mitochondria).  
For experiments where redox state was manipulated, energized mitochondria were treated 
with either 200 μM of the thiol-oxidant diamide or 2 mM of the thiol reductant dithiothreitol 
(DTT) beginning 10 min prior to beginning calcium pulses. These concentrations of diamide and 
DTT have previously been used by our group and others [87, 88]. For studies where isolated 
mitochondria were treated with MTP-131, incubated mitochondria were treated with 1 nM MTP-
131 for 10 min prior to beginning calcium pulses. 
In vivo MTP-131 treatment  
To determine if increased endogenous mitochondrial ROS production was responsible for 
PTP redox modifications, a subset of rats was treated daily with MTP-131. MTP-131 is a small 
cell-permeable peptide analogous to SS-02 and SS-31, and is currently being utilized in clinical 
studies [80]. In this cohort, MTP-131 (1.5 mg/kg in 0.9% saline) was injected (i.p.) daily for the 
4 days prior to the mitochondrial isolation day, and calcium retention was determined as 
described in section 2.6. 
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Isolated heart studies 
For whole-heart studies, rat hearts were perfused (perfusion pressure of 75 mm Hg) in a 
retrograde fashion on a modified Langendorff apparatus using an established protocol by our 
group [87, 89, 90]. Hearts were perfused with a modified Krebs–Henseleit buffer containing (in 
mM): 118 NaCl, 24 NaHCO3, 4.75 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.0 CaCl2, and 10 glucose 
(gassed with 95/5% O2/CO2). Hearts were bathed in a buffer-filled perfusion chamber 
maintained at 37°C for the duration of the experiments. Following the initiation of perfusion, 
hearts were instrumented for the simultaneous observation of mechanical and electrical function. 
A buffer-filled latex balloon (size 5, Harvard Apparatus, Holliston, MA, USA), calibrated at the 
beginning of each day using a digital manometer, was inserted into the left ventricle (via the 
mitral valve) for the measurement of left ventricular developed pressure (LVDP), with balloon 
volume adjusted to establish a diastolic pressure of 5–8 mm Hg. Three electrodes were placed 
into the buffer-filled perfusion chamber for the measurement of volume-conducted ECG. 
Coronary flow rates were monitored constantly with a flow probe (Transconic Systems, Ithaca, 
NY, USA) connected in series with the perfusion line, and normalized to heart wet weight (in 
grams) at the end of each experiment. All physiological parameters were continuously monitored 
and stored on a personal computer using commercially available software (Chart, AD 
Instruments, Colorado Springs, CO, USA). Heart rate was calculated using the LVDP trace, and 
maximal rates of contraction and relaxation (±dP/dt) were calculated using the derivative of the 
LVDP trace. 
Ischemia/reperfusion protocol and drug treatments 
Following a 10 minute baseline period, ischemia/reperfusion was initiated similarly to 
that described previously by our group [89]. Hearts were exposed to global no-flow ischemia by 
stopping perfusion for 20 min. At the end of the index ischemia, static buffer from the perfusion 
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lines was washed out (via an accessory port proximal to the aortic cannula), and reperfusion 
ensued for 2 h either with control buffer or buffer containing one of three experimental 
compounds. 
Hearts were reperfused with Krebs buffer alone (control), or Krebs buffer containing the 
PTP blocker NIM811 (5 μM) [82], the mitochondria-targeted peptide MTP-131 (1 nM) [2], the 
calcium uniporter blocker minocycline (1 μM), or the reducing agent DTT (2 mM). At the end of 
reperfusion, the left ventricle was dissected, sliced into 5 mm-thick slices, incubated in 1% 
triphenyltetrazolium chloride (TTC) for 10 min (37°C) and digitally photographed for 
subsequent infarct size analysis. Infarct size was expressed as a percentage of the left ventricle 
(calculated using ImageJ software, NIH, Bethesda, MD, USA). Arrhythmias were scored as 
described previously by our group [87, 89, 90] and were in accordance with the Lambeth 
Conventions [91, 92]. 
Materials 
Unless otherwise noted, all reagents used were obtained from Sigma-Aldrich. Calcium 
green 5 N salt was purchased from Invitrogen (Carlsbad, CA, USA). NIM811 was a gift from 
Novartis, and MTP-131 was obtained from Stealth Peptides Inc. 
Statistical analysis 
Data are presented as mean±SEM. Statistical analyses were performed using an ANOVA 
with Newman–Keuls post-hoc analysis for comparison between groups. Total glutathione, 
GSSG, GSH/GSSG, glutathione reductase, glutathione peroxidase, and ANT redox state were 
compared between control and diabetic animals with a Student's t test. For all comparisons, the 
level of significance was established at P<0.05. 
Results 
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Animal morphology 
Rat body weights, heart weights (corrected for body weight) and fasting levels of glucose 
and free fatty acids are presented in Table 1. STZ-treated rats had significantly lower body 
weights as well as lower heart weights when compared to non-STZ-treated rats (P<0.05). As 
expected, STZ-treated rats displayed significantly higher fasting glucose levels when compared 
to non-STZ-treated rats (P<0.05). Circulating non-esterified free fatty acid levels (NEFFA) were 
not different between control and STZ groups (P>0.05). Daily treatment of diabetic animals with 
MTP-131 had no effect on circulating glucose or NEFFA levels (427±31 mg/dL and 449±73 μM 
for glucose and NEFFA, respectively; P>0.05 compared to pre-treatment levels). 
Myocardial glutathione 
Myocardial glutathione content is presented in Fig. 2. Although we observed no 
significant differences in total glutathione content between control and STZ treated rats (Fig. 
2A), diabetic animals displayed higher levels of oxidized glutathione (GSSG) and a significant 
reduction in GSH/GSSG (Figs. 2B and C, respectively; P<0.05). We did not observe differences 
in glutathione reductase or glutathione peroxidase in control versus STZ-treated animals in the 
study (data presented in Table 1). 
Thiol redox state of the ANT 
To determine if the oxidized myocardial thiol pool translated to oxidation of the 
permeability transition pore, we probed the adenine nucleotide translocase (ANT) to determine 
the redox state of free reactive thiols. There were no differences in the content of ANT protein 
between control and diabetic animals (Fig. 3A). Fluorescent maleimide labeling revealed that the 
ANT was more oxidized in diabetic animals compared to controls (Fig. 3B, P<0.05 versus 
control). 
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Mitochondrial permeability transition pore opening 
We found no difference in the quality of our cardiac mitochondria, as reflected by 
respiratory control ratio. Respiratory control ratios were 8.2±1.5 and 8.7±1.5 in control and 
diabetic mitochondria, respectively (P>0.05). Fluorescence data for Ca-induced PTP opening as 
well as representative traces is depicted in Fig. 4. Isolated mitochondria from the left ventricle of 
STZ treated rats required significantly less calcium in order to induce PTP opening when 
compared to non-STZ treated rats (P<0.05), demonstrating that STZ treated rats have an 
enhanced sensitivity to Ca-induced PTP opening. The enhanced sensitivity to PTP opening in 
STZ treated rats was significantly decreased (P<0.05) when isolated mitochondria were treated 
with 2 mM dithiothreitol, when animals received daily i.p. injections of 1.5 mg/kg MTP-131 for 
the 4 days leading up to the experimental day, or when isolated mitochondria were directly 
treated with 1 nM MTP-131. Treatment with 200 μM diamide significantly increased the 
sensitivity to Ca-induced PTP opening in non-STZ treated rats (P<0.05) but had no effect on Ca-
induced PTP sensitivity in STZ treated rats. Treating non-diabetic mitochondria with DTT or 
MTP-131 (either directly or following daily MTP-131 injections) had no significant effect on 
calcium retention capacity (P>0.05 versus untreated mitochondria; Fig. 4B). 
Effects of minocycline and NIM811 on cardiac mitochondria 
To validate the pharmacological approaches used in whole-heart studies, we treated 
isolated mitochondria with minocycline and NIM811. These data are presented in Fig. 5. 
Incubation of mitochondria with 1 μM minocycline was just as effective at blocking 
mitochondrial calcium influx as Ru360, a well-characterized mitochondria uniporter antagonist 
(Fig. 5A). The PTP blocker NIM811 significantly prolonged PTP opening (Fig. 5B), leading to a 
mean calcium retention capacity of 1067±38 nmol calcium per mg mitochondrial protein. These 
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data support our use of these compounds in the intact heart to block PTP either directly (with 
NIM811), or indirectly (with minocycline to reduce mitochondrial calcium influx). 
Infarct size 
Infarct sizes for hearts in the study are presented in Fig. 6. Hearts from diabetic rats were 
more susceptible to IR injury, with infarct sizes of 60±4% of the area-at-risk (vs. 46±2% in non-
diabetics; P<0.05). Administration of 5 μM NIM811, 1 nM MTP-131, or 1 μM minocycline at 
the onset of reperfusion significantly reduced infarct sizes in both control and diabetic animals. 
Control hearts treated with NIM811, MTP-131, and minocycline displayed similar reductions 
that were statistically different from untreated hearts (P<0.05, ANOVA). Infarct sizes in diabetic 
animals were also reduced by NIM811, MTP-131, and minocycline, to levels that were 
significantly different from the diabetic untreated group (P<0.05, ANOVA). Our post-hoc 
analyses revealed that control animals treated with NIM811, MTP-131, or minocycline were not 
different from diabetic counterparts treated with the same compound (P<0.05 for each post-hoc 
comparison). 
A subset of hearts was perfused with the reducing agent DTT to determine if the 
beneficial effects of DTT in isolated mitochondria translated to cardioprotection in the intact 
organ. Interestingly, perfusion with DTT led to potent vasoconstriction that was especially 
prominent in diabetic animals, with coronary flow decreasing to <3 mL/min g in 50% of diabetic 
hearts before the onset of ischemia. This robust decline in coronary flow effectively exacerbated 
the duration of ischemic insult, and led to infarct size expansion to 67±5% of the area-at-risk in 
diabetic hearts treated with DTT. These findings are consistent with the work of Okazaki et al., 
where diabetic hearts treated with DTT showed increased ischemia/reperfusion injury and 
vasoconstriction [93]. Neither the infarct size expansion nor the decline in coronary flow in 
control animals treated with DTT went to the level of diabetic animals. Infarct size was 58±4% 
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of the area at risk, and mean coronary flow was 6.1±1.1 mL/min g in non-diabetic hearts treated 
with DTT prior to ischemia. 
Hemodynamics and cardiac arrhythmia 
Hemodynamics are presented in Tables 2 and 3. There were no significant differences 
between groups in left ventricular function or coronary flow before the ischemic period or at the 
end of the reperfusion protocol (P>0.05). Arrhythmia scores are presented in Fig. 7. There were 
no differences in the incidence of arrhythmias between any of the experimental groups (P>0.05). 
Discussion 
This study was conducted to determine the contributions of mitochondria-derived ROS 
and mitochondrial calcium to the increased permeability transition and augmented 
ischemia/reperfusion injury observed in diabetic heart. The major observations from this work 
are as follows: First, myocardial thiol redox state was more oxidized in the diabetic heart, and 
this translated to increased oxidation of the adenine nucleotide translocase (ANT), a putative 
PTP component. Second, the enhanced permeability transition pore (PTP) opening in the diabetic 
heart was reversed by thiol reductants, and chemical thiol oxidation of diabetic mitochondria had 
no additional effect. Third, diabetic animals treated with a cell-permeable peptide known to 
reduce mitochondrial ROS production displayed significant improvements in PTP sensitivity. 
Finally, the exacerbated cardiac injury in the intact diabetic heart is attenuated to non-diabetic 
levels with three distinct pharmacological strategies aimed at keeping PTP closed during 
reperfusion. Taken together, this study provides novel insight into the mechanisms responsible 
for increased ischemia/reperfusion injury in the diabetic heart.  
Enhanced PTP opening in diabetic heart mitochondria 
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The development of ischemia/reperfusion injury is multi-factorial, and is generally 
attributed to a combination of tissue necrosis and apoptosis (reviewed in [8]). During the initial 
phases of ischemia/reperfusion, the majority of tissue death is likely from necrosis [72], and 
blocking the PTP reduces cardiac necrotic injury in animals (reviewed in [9, 73-75]) and in a 
recent human clinical trial [94].  
Increased susceptibility to cardiac injury in diabetes is evident in both human and animal 
studies [19, 20, 65-68, 95], and a growing body of literature indicates that augmented PTP 
opening in the diabetic heart may be (at least partially) responsible for the augmented cardiac 
injury. Our observation that diabetic rat heart mitochondria display an enhanced propensity for 
PTP opening corroborates previous work in mice [71], rats [69, 70], and human atrium [66]. 
While there is a clear role for PTP opening in the diabetic heart, the underlying mechanisms 
responsible for the augmented PTP opening in the diabetic heart are not fully understood. 
Among the cellular factors that promote PTP opening, high levels of ROS are known to sensitize 
the PTP to calcium-induced opening (reviewed in [9, 12, 72, 73, 96]). Myocardial ROS handling 
is altered in the diabetic state, with diabetic hearts displaying both increased ROS production 
[20, 97-99] and decreased ROS scavenging [22-24].  
Among the anti-oxidant scavenging mechanisms, the reduced/oxidized glutathione 
couple (GSH/GSSG) is particularly important in mitochondrial physiology (recently reviewed in 
[100]). The GSH/GSSG couple is the largest capacity thiol buffer in the cell [101], and we 
previously showed that oxidizing GSH creates instability in mitochondrial membrane potential 
and evokes cardiac electromechanical dysfunction under normoxic conditions [87]. Our 
observation that the GSH/GSSG is significantly oxidized in diabetic hearts corroborates studies 
in human diabetic atrium [102] as well as experimental models of diabetes [68, 78, 79, 103, 104].  
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Given that decreased GSH/GSSG is known to promote PTP opening [105], we believe 
that the diabetic heart is characterized by an oxidative shift in the cellular redox environment, 
which increases PTP open probability due to thiol-dependent modifications of the pore. To 
determine if PTP thiols are more oxidized in the diabetic heart, we used fluorescently labeled 
maleimide to determine the thiol redox state of the adenine nucleotide translocase (ANT), a 
putative PTP component. We found that the ANT is more oxidized in the diabetic heart, 
supporting the results from our pharmacology experiments in isolated mitochondria. While these 
are the first findings to demonstrate basal ANT oxidation in the diabetic heart, we must 
acknowledge that the protein components that combine to form the PTP are still being debated 
[9, 96], and further studies will be needed to determine if other postulated components of the 
PTP (such as the phosphate carrier and/or cyclophilin-D) are also oxidized in diabetic 
myocardium.  
A few studies in non-diabetic animals have demonstrated that PTP open probability is 
augmented with thiol-oxidants and delayed with thiol-reductants [76], ostensibly by redox 
modulation of pore components [106]. To the best of our knowledge this is the first study to 
examine the relationship between thiol redox state and PTP opening in the diabetic heart, and 
provides a crucial link between increased ROS production and PTP opening that are 
characteristic of the diabetic heart.  
We demonstrated that the increased PTP open probability in diabetic mitochondria is 
reversed with the thiol reducing agent DTT, while DTT had no effect on PTP opening in non-
diabetic mitochondria. This corroborates previous findings that treatment with a reducing agent 
only decreases the sensitivity to Ca-induced PTP opening when conditions of oxidative stress are 
prevailing [88]. Interestingly, we did not observe a further shift in PTP open probability in 
diabetic mitochondria treated with diamide, suggesting that PTP thiols are oxidized at rest, 
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perhaps to a physiological maximum that cannot be surpassed with additional chemical oxidation 
of the thiol pool.  
In addition to the partial rescue of PTP sensitivity that we observed with a thiol reductant, 
diabetic animals that were treated with a mitochondria-targeted ROS suppressant (either with 
daily injections or by directly treating isolated mitochondria) also showed significant 
improvements in mitochondrial calcium retention. MTP-131 belongs to a novel class of cell 
permeable small peptides that selectively target mitochondria and localize at the inner 
mitochondrial membrane. MTP-131 is known to reduce mitochondrial ROS levels in several 
different models and protect against cell death induced by a variety of chemical and biological 
stressors (reviewed in [3, 80]).  
Our demonstration that MTP-131 improved PTP sensitivity in the diabetic heart is novel, 
and provides strong evidence that mitochondria-derived ROS in the diabetic heart causes shifts 
in the thiol redox state, ultimately leading to increased PTP opening. Our data suggest that MTP-
131 is not a direct PTP blocker, as calcium retention capacity in control animals was not affected 
by this compound (contrast with NIM811, see Figs. 4 and 5). Rather, it appears that MTP-131 is 
acting to lower ROS levels in vivo, ostensibly keeping PTP thiols in a more reduced state by 
maintaining GSH/GSSG. While speculative, these data are in agreement with previous studies 
showing better maintenance of the thiol redox pool in animals treated with the MTP-131 analog 
SS-31 [107]. This idea is further supported by observations that ROS production is minimal 
when mitochondria are respiring on glutamate/malate [108], implying that MTP-131 should have 
no effect on PTP opening if an oxidant burden is not present.  
Interestingly, neither the thiol-reductant nor MTP-131 restored PTP sensitivity to non-
diabetic levels. Several possibilities could explain these findings. First, the expression of putative 
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pore components (specifically, cyclophilin-D) is elevated in diabetic hearts [71, 109], which may 
confound our results since more cyclophilin-D protein is available to associate with the pore. 
Second, in addition to the pore regulation by calcium and ROS, ADP and pH also regulate PTP 
opening. Several studies have found differences in mitochondrial energetics in the diabetic heart 
[68], which may explain why we did not fully reverse the PTP sensitivity. We noted no 
difference in the quality of our mitochondrial preparations (as reflected by similar respiratory 
control ratios) or the state IV respiratory rates, indicating that differences in uncoupling were 
likely not present in our model.  
Decreasing reperfusion injury by targeting cardiac mitochondria 
Our data in isolated mitochondria indicated a clear difference in the susceptibility to PTP 
opening between non-diabetic and diabetic animals. These findings are in agreement with our 
observations in intact hearts, where we saw a significantly greater extent of ischemia/reperfusion 
injury in diabetic myocardium. Infarct sizes in diabetic hearts were approximately 30% larger 
than non-diabetic counterparts, which is in general agreement with a number of studies in the 
literature indicating that diabetic hearts are more susceptible to ischemia/reperfusion injury [110-
115]. We conducted studies in the intact heart to determine if approaches that diminish the open 
probability of the PTP salvaged cardiac tissue. We used 3 compounds targeted at heart 
mitochondria to decrease reperfusion injury: direct inhibition of the PTP with NIM811, and 
indirect inhibition by keeping matrix calcium and ROS low with minocycline and MTP-131, 
respectively. To increase the clinical relevance of our findings we only administered the 
compounds at the onset of reperfusion (as opposed to pre-treatment, which has limited clinical 
application [116]). Administration of NIM811, MTP-131, or minocycline reduced infarct size in 
non-diabetic animals, with no differences in the extent of cardioprotection between the 
compounds. The infarct-salvaging that we observed in our non-diabetic animals corroborates 
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previous studies in the literature where these treatments reduced ischemia/reperfusion injury in 
otherwise healthy animals [3, 117, 118].  
Directly blocking the PTP in diabetic hearts 
In our whole heart experiments, we directly blocked the PTP with NIM811, an analog to 
cyclosporin-A that shows greater specificity for cyclophilin D. A number of studies have shown 
that blocking the PTP with cyclosporin-A decreases infarct size [75, 77, 81, 119, 120], including 
recent studies in human clinical trials [94]. Although promising, the use of CsA is confounded by 
several problems, including a narrow therapeutic window [121], potentially harmful effects to 
the microvasculature [122-124], deleterious effects on long-term myocardial function [125], 
suppression of mitochondrial respiration [81], nephrotoxicity [126], and immunosuppression 
[127]. Given that diabetics are known to have high rates of microvascular dysfunction [128], 
both cardiac and mitochondrial dysfunction [68], renal failure [129] and depressed immune 
function [130], cyclosporin-A may be contraindicated in this patient population. Accordingly, we 
employed NIM811 to block PTP opening in isolated hearts. NIM811 is a non-
immunosuppressive derivative of cyclosporin-A and is very effective at blocking PTP across a 
wider range of doses [81, 131]. NIM811 blocks PTP formation by selectively binding matrix 
cyclophilin-D, but unlike cyclosporin-A it does not bind cyclophilin A [131]. Our finding that 
NIM811 protected diabetic hearts from injury is in agreement with several previous studies 
showing infarct size reduction with NIM811 [81, 117], although this is the first study to 
demonstrate its efficacy in a diseased population. 
Indirectly blocking PTP by targeting mitochondrial calcium and ROS 
Given that PTP open probability is promoted by calcium and ROS [9, 12, 72, 96], we 
used two novel agents targeted at mitochondrial calcium and ROS to decrease reperfusion injury 
in diabetic hearts by indirectly reducing the open probability of PTP. Calcium entry into the 
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matrix occurs through the mitochondrial calcium uniporter [52]. Both ruthenium red and Ru360 
block mitochondrial calcium influx through the uniporter [132, 133], but these compounds have 
nonspecific effects on intracellular calcium transients [132, 134]. Furthermore, while effective in 
isolated mitochondrial studies, Ru360 appears to be impermeable across cell membranes, 
precluding therapeutic use [135, 136]. We used the tetracycline anti-biotic minocycline to block 
matrix calcium influx. The ability of minocycline to block mitochondrial calcium fluxes was 
recently demonstrated in liver mitochondria [82], and our data herein demonstrate that 
minocycline is just as effective as Ru360 at blocking mitochondrial calcium influx in cardiac 
mitochondria. Minocycline is highly permeable to heart cells [118], and has no discernable effect 
on myocyte calcium handling or baseline cardiac hemodynamics [137], making it an attractive 
candidate to modulate mitochondrial calcium fluxes in the intact heart/animal. In our study, 
blocking mitochondrial calcium influx at the onset of reperfusion was just as effective at 
salvaging tissue as directly blocking the PTP. Some studies have suggested that minocycline 
depolarizes cardiac mitochondria, but only at concentrations at least two orders of magnitude 
higher than used herein [138, 139]. Indeed, we found no effect of minocycline on mitochondrial 
membrane potential (RC Sloan and DA Brown, unpublished observations using 
triphenylphoshonium uptake). This suggests that the protective effects observed in our study are 
due to inhibiting calcium influx, and not by an uncoupling mechanism. To determine if indirectly 
inhibiting PTP opening by lowering mitochondrial ROS levels decreased reperfusion injury in 
diabetic hearts, we used the novel cell permeable compound MTP-131. Our observation in 
diabetic animals that lowering mitochondrial ROS levels at reperfusion reduces infarct size is 
novel. Although this is in general agreement with other studies where over-expression of anti-
oxidants protected diabetic hearts against post-ischemic injury [140, 141], we did not observe 
differences in functional recovery in any of our drug-treated groups herein. Furthermore, we saw 
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no beneficial effects on the incidence of cardiac arrhythmia with any of the strategies targeting 
PTP, providing further evidence that PTP blockers do not markedly influence the 
incidence/severity of reperfusion arrhythmia (recently reviewed in [142]). Given that the thiol-
reductant DTT partially reversed the PTP sensitivity in isolated diabetic mitochondria, we also 
administered DTT to intact hearts to determine if this translated to infarct salvage. Interestingly, 
we observed significant vasoconstriction in diabetic animals that were treated with DTT prior to 
ischemia, which led to expansion of the infarct size. These effects of DTT on diabetic hearts are 
in agreement with another recent study where DTT reduced basal coronary flow by ~40% and 
increased infarct size in diabetic hearts [93], and suggest that the reduction in coronary flow in 
diabetic animals exacerbated the extent of injury in diabetic animals. Although the mechanisms 
underlying DTT-dependent vasoconstriction in diabetics are beyond the scope of our study, it is 
tempting to speculate that DTT may be disrupting the bioavailability of nitric oxide by 
interfering with other thiol-dependent signaling (such as S-nitrosylthiol modifications) in the 
coronary endothelium. Clearly further study is warranted to fully understand the effects of DTT 
in the diabetic vasculature. 
Study limitations 
One limitation to our study is that streptozotocin was used to induce diabetes. Although 
this model more closely resembles Type I diabetes, there are a number of similarities to Type II 
diabetes models. Similar to both humans and animal models of type 2 diabetes, hearts from STZ-
induced diabetic rats display alterations in myocardial calcium handling, substrate utilization, 
mitochondrial energetics, and enhanced oxidative stress (recently reviewed in [19]). 
Conclusions 
In summary, these experiments provide evidence that augmented reperfusion injury 
observed in the diabetic heart is a consequence of enhanced susceptibility to mitochondrial 
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permeability transition. Diabetic hearts displayed oxidative shifts in the myocardial glutathione 
pool, and this translated to increased oxidation of PTP components, namely the ANT. Increased 
PTP opening in diabetic heart mitochondria was partially reversed either with a thiol-reductant or 
daily treatment with a mitochondria-targeting peptide, suggesting that greater ROS burden in the 
diabetic heart shifts the intracellular redox environment and promotes PTP opening. In the whole 
heart, three novel pharmacological approaches at the onset of reperfusion significantly decreased 
injury, suggesting that either direct or indirect inhibition of PTP has significant clinical potential 
to reduce the burden of ischemic heart disease among the rapidly growing diabetic population.  
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Table 1 
Animal morphology and baseline biochemical parameters. Data are presented as mean ± SEM. 
 
 Control STZ 
Body weight (g) 348 ± 6.8 307 ± 12.4* 
Heart weight/body weight (mg/g) 5.29 ± 0.12 4.44 ± 0.17* 
Fasting glucose (mg/dL) 114 ± 1.4 495 ± 21.9* 
Circulating non-esterfied free fatty acids (µM) 448 ± 63 390 ± 62 
Glutathione reductase activity (U/g protein) 70 ± 13 55 ± 7 
Glutathione peroxidase activity (U/g protein) 452 ± 43 345 ± 80 
*P<0.05 versus control. 
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Figure 2. Glutathione content in the diabetic heart. A. Total glutathione in control and diabetic 
(STZ) left ventricles. B. Oxidized glutathione (GSSG) content from control and diabetic (STZ) 
hearts. C. Ratio of reduced to oxidized glutathione (GSH/GSSG) in diabetic hearts in the study. 
*P<0.05 versus control. 
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Figure 3. Adenine nucleotide translocase (ANT) content and redox state in hearts from the 
study. A. Total content of ANT in hearts from the study using Western blot. B. Levels of reduced 
thiols on the ANT assessed using immunoprecipitation and serial maleimide labeling to 
fluorescently label reduced \SH groups. Confirmation of the assay sensitivity is provided where 
the thiol reductant dithiothreitol (DTT) and hydrogen peroxide (H2O2) led to ANT reduction and 
oxidation, respectively. *P<0.05 versus non-diabetic. 
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Figure 4. Influence of thiol redox modifications on Ca-induced opening of the permeability 
transition pore in isolated cardiac mitochondria. A. Representative extramitochondrial calcium 
fluorescence traces from diabetic mitochondria following 50 nmol pulses of CaCl2 to induce 
permeability transition. B. Quantification of calcium retention capacity in isolated mitochondria 
from non-diabetic and diabetic animals. Mitochondria were either treated with diamide (thiol 
oxidizing agent) or dithiothreitol (DTT; thiol reducing agent). In other studies we examined the 
effect of the mitochondria-targeting ROS suppressant MTP-131. Animals were either pre-treated 
with MTP-131 for 4 days prior to isolated mitochondria experiments (MTP-131 Pre-Tx), or the 
effect of MTP-131 on calcium retention capacity was directly examined by treating mitochondria 
with 1 nM MTP-131 for 10min prior to beginning calciumpulses. *P<0.05 versus non-drug 
treated control; #P<0.05 versus non-drug treated STZ; n=6–14 calcium retention experiments in 
each group. Abbreviations: STZ, streptozotocin-induced diabetes; PTP, mitochondrial 
permeability transition pore. 
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Figure 5. Influence of compounds used in whole-heart studies on calcium uptake and PTP 
opening in isolated cardiac mitochondria. A. Extramitochondrial traces showing that the 
tetracycline anti-biotic minocycline (1 μM) is just as effective as Ru360 in inhibiting 
mitochondrial calcium uptake in isolated cardiac mitochondria. B. Representative traces 
indicating delayed PTP opening in mitochondria treated with 5 μM NIM811 (mean calcium 
retention was 1067±38 nmol calcium per mg mitochondrial protein). Abbreviations: STZ, 
streptozotocin-induced diabetes. 
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Figure 6. Infarct sizes in hearts in the study. Data are presented as mean±SEM; *P<0.05 versus 
control; #P<0.05 versus non-drug treated STZ; n=5–10 in each group. All compounds were 
administered at the onset of reperfusion. Abbreviations: STZ, streptozotocin-induced diabetes. 
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Table 2 
 
Baseline hemodynamics for hearts in the study. 
 
 Control STZ 
LVDP (mmHg) 123 ± 12 119 ± 9 
+dP/dt (mmHg/s) 4312 ± 444 3580 ± 367 
-dP/dt (mmHg/s) -2791 ± 223 -2266 ± 254 
Coronary flow (mL/min/g heart wet wt) 8.3 ± 0.7 8.8 ± 1.5 
 
Abbreviations; LVDP, left ventricular developed pressure; +dP/dt, maximal rate of contraction; -
dP/dt, maximal rate of relaxation; n = 5-10 in each group. 
40 
 
Table 3 
 
Cardiac hemodynamics at the end of the 2 hour reperfusion in control and diabetic (STZ) rat 
hearts. 
 
 
LVDP 
(mmHg) 
+dP/dt 
(mmHg/s) 
-dP/dt 
(mmHg/s) 
Coronary flow 
(mL/min g wet wt) 
Control 30 ± 7 768 ± 96 -535 ± 63 3.8 ± 0.4 
Control + NIM811 22 ± 3 734 ± 101 -518 ± 73 2.5 ± 0.3 
Control + Minocycline 36 ± 6 1239 ± 195 -786 ± 101 4.1 ± 0.2 
Control + MTP-131 34 ± 4 1069 ± 110 -704 ± 63 3.7 ± 0.2 
STZ 26 ± 3 816 ± 126 -489 ± 63 4.3 ± 0.7 
STZ + NIM811 25 ± 3 703 ± 117 -456 ± 57 3.7 ± 0.2 
STZ+ Minocycline 32 ± 9 758 ± 173 -456 ± 57 4.3 ± 0.8 
STZ + MTP-131 24 ± 4 789 ± 174 -475 ± 75 4.0 ± 0.6 
 
Abbreviations; LVDP, left ventricular developed pressure; +dP/dt, maximal rate of contraction; -
dP/dt, maximal rate of relaxation; all pharmacological compounds were administered beginning 
at the onset of reperfusion. n = 5-10 in each group. 
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Figure 7. Quantification of arrhythmia scores from isolated rat hearts following 20 min of 
ischemia and 120 min of reperfusion. Data are presented as mean±SEM. There were no 
significant differences between groups, N=5–10 in each group. Abbreviations: STZ, 
streptozotocin-induced diabetes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3:  The mitochondria-targeting peptide Bendavia restores mitochondrial function 
in diabetic hearts by improving mitochondrial calcium handling and oxidative 
phosphorylation 
 
Introduction 
Diabetic cardiomyopathy is one of the leading causes of heart failure in diabetic patients; 
however, effective treatment for this disease is still lacking. Most medical care for diabetic 
patients focuses on glycemic control despite the fact that 60% of these patients with acceptable 
glycemic control and with no clinically detectable heart disease still show signs of a 
dysfunctional myocardium when screened with Valsalva maneuver and pulmonary venous 
recording [143, 144]. Therapies targeting the dysfunctional diabetic myocardium, especially in 
the early asymptomatic stages, that can reduce the progression to heart failure are currently 
lacking.  
Recent evidence suggests that decrements in bioenergetics coordination are centrally 
involved in diabetic cardiomyopathy. Indeed, while the healthy heart is proficient at adjusting its 
energetic supply to demand, the diabetic heart has a very limited capacity of energy matching 
[17, 18]. A growing body of literature indicates that alterations in mitochondrial function may be 
responsible for the increased cardiac dysfunction observed in diabetes (reviewed in [19]). 
A key signaling molecule in sustaining adequate cardiac function with changing 
metabolic demand is Ca. The mitochondrial uptake of Ca is essential for adjusting cardiac 
function to changing metabolic needs, since Ca stimulates oxidative phosphorylation by 
activating several enzymes of the Krebs Cycle as well as the ATP-synthase of the respiratory 
chain [46-51].  
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Ca entry into mitochondria occurs through the mitochondrial Ca uniporter (MCU), an ion 
channel within the inner mitochondrial membrane whose molecular identity has recently been 
elucidated [52, 53], and this process is regulated by at least 2 newly characterized mitochondrial 
proteins: Mitochondrial Ca uptake 1 (MICU1) [54] and mitochondrial Ca uptake regulator 1 
(MCUR1) [55]. While it is well known that mitochondrial calcium influx is decreased in the 
diabetic heart [57-59], there are no data relating this decrease to changes in the mitochondrial 
proteins handling Ca uptake.  Accordingly, whether these proteins can be regulated by a 
therapeutic intervention is not known. 
Therapies that can improve overall mitochondrial function in the diabetic heart have clear 
potential to mitigate the burdens associated with diabetic cardiomyopathy. Bendavia is a cell-
permeable mitochondria-targeting peptide being currently tested in clinical trials for 
cardiovascular and renal disease. We recently showed that Bendavia is able to delay the opening 
of mitochondrial permeability transition pore, and reduce ischemia reperfusion injury in diabetic 
hearts [62].  
The aim of this study was to determine if daily Bendavia treatment could result in improved 
mitochondrial function by: 1) reversing the decrement in mitochondrial calcium uptake by 
regulating the levels of mitochondrial Ca uptake proteins, 2) ameliorating the oxidative 
phosphorylation machinery, and 3) improving the mitochondrial respiratory capacity.  
Methods 
Materials 
Unless otherwise noted, all reagents used were obtained from Sigma-Aldrich. Ca green 5 
N salt probe and Amplex Ultra Red Reagent (AUR) were purchased from Invitrogen (Carlsbad, 
CA, USA), Bendavia was obtained from Stealth Peptides Inc. 
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Experimental animals 
All animal procedures received prior approval by the East Carolina University 
Institutional Animal Care and Use Committee. Male Sprague–Dawley rats (7–9 weeks old) were 
housed in a temperature (22°C) and light-controlled (12 hour light/12 hour dark) environment 
and fed standard rat chow (Research Diets, New Brunswick, NJ, USA) and water ad libitum. 
After 5 days of acclimation to the facility, diabetes was induced with a single intraperitoneal 
(i.p.) injection of streptozotocin (STZ, 65 mg/kg) dissolved in 100 mM sodium citrate (pH=4.5) 
following a 12-hour overnight fast. Control animals received an i.p. injection of sodium citrate. 
All experiments were performed 4 weeks following STZ injection. Blood glucose was 
determined using blood from tail vein and a commercially available glucometer (One Touch 
Ultra 2, LifeScan, Milpitas, CA, USA). On the day of experimentation, rats were anesthetized 
with a ketamine/xylazine cocktail (90 mg/kg and 10 mg/kg, respectively; i.p. injection) and 
hearts were removed via bilateral thoracotomy, and studied on Langendorff, used to prepare 
skinned cardiac fibers, isolated mitochondria, or flash frozen and later used for western blots. 
The hearts used for Langendorff studies were collected at the end, dried out and the dry weight 
used to normalize the myocardial oxygen consumption. 
In vivo treatment with Bendavia 
Animals received an intra-peritoneal injection of either Bendavia (1.5 mg/kg in 0.9% 
saline) if they were in the control-Bendavia and STZ-Bendavia groups, or an equivalent volume 
of saline if they were in the groups of control-saline and STZ-saline. These injections were given 
daily during the last 4 days post-STZ/citrate injection and prior to studying the animals at 4 
weeks post STZ-injection.  
Isolated Heart Studies 
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For whole-heart studies, rat hearts were perfused (perfusion pressure of 75 mmHg) in a 
retrograde fashion on a modified Langendorff apparatus using an established protocol by our 
group [62, 87].  Hearts were perfused with a modified Krebs-Henseleit buffer containing (in 
mM): 118 NaCl, 24 NaHCO3, 4.75 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.0 CaCl2, and 10 glucose 
(gassed with 95/5% O2/CO2).  Hearts were bathed in a buffer-filled perfusion chamber 
maintained at 37C for the duration of the experiments. Following the initiation of perfusion, 
hearts were instrumented for the simultaneous evaluation of mechanical and electrical function.  
A buffer-filled latex balloon (size 5, Harvard Apparatus, Holliston, MA, USA), calibrated at the 
beginning of each day using a digital manometer, was inserted into the left ventricle (via the 
mitral valve) for the measurement of left ventricular developed pressure (LVDP), with balloon 
volume adjusted to establish a diastolic pressure of 5-8 mmHg.  Three electrodes were placed 
into the buffer-filled perfusion chamber for the measurement of volume-conducted ECG. 
Coronary flow rates were monitored throughout the experiment with a flow probe (Transconic 
Systems, Ithaca, NY, USA) connected in series with the perfusion line. All hemodynamic 
parameters were continuously monitored and stored on a personal computer using commercially 
available software (Chart, AD Instruments, Colorado Springs, CO, USA).  Heart rate was 
calculated using the LVDP trace.  
Energy supply-demand matching protocol  
Following a 20 min equilibration and a 10 minute baseline period, the hearts were paced 
for 3 minutes at 5 Hz then for 3 minutes at 7 Hz. The pacing was stopped and the hearts received 
a bolus of 5μM carbonyl cyanide p-trifluoromethoxy phenylhydrazone (FCCP) via an injection 
port to evaluate the maximal mitochondrial respiratory capacity. The wet weight of the whole 
heart, and the left ventricle were recorded and the whole cardiac tissue was dried for 24h to get 
the heart’s dry weight which was used to normalize the myocardial oxygen consumption. 
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Preparation of skinned cardiac fibers  
Skinned cardiac fibers were prepared according to a method described by Anderson and 
Neufer (2006) [145]. Following the heart excision from anesthetized animals, the left ventricle 
was dissected and placed on a petri dish containing ice-cold buffer X containing in (mM): 7.23 
K2EGTA, 2.77 CaK2EGTA, 20 Imidazole, 20 Taurine, 5.7 ATP, 14.3 Phosphocreatine, 6.56 
MgCl2-6H2O and 50 MES; pH 7.1. All fat and connective tissue was removed under a dissecting 
microscope, and small cardiac fiber bundles (5-7 mg of wet weight) were prepared. Fiber 
bundles were permeabilized using 50μg/ml saponin at 4°C for 20 min. Permeabilized fiber 
bundles were then washed, 3 times for 5 min each, in ice-cold buffer Z containing in (mM): 110 
K-MES, 35 KCL, 1 EGTA, 5 K2HPO4, 3 MgCl2-6H2O, and 5 mg/ml BSA; pH 7.4. The fiber 
bundles were kept at 4°C in buffer Z until analysis. 
Analysis of mitochondrial function in skinned cardiac fibers 
All experiments were conducted at 37°C in presence of 20 μM blebbistatin to prevent 
contraction as previously described [146]. We used the Oroboros system (Oroboros Instruments, 
Innsbruck, Austria) to measure O2 consumption. Buffer Z was used as respiration medium and 
O2 consumption was monitored during a substrate-inhibitor titration protocol in order to obtain a 
step-by-step analysis of various components of the mitochondrial respiratory chain as described 
by Kuznestov et al. (2008) [147]. The addition of substrates and inhibitors was done in the 
following sequence: Glutamate/malate (10mM/5mM), ADP (2 mM), Rotenone (0.5 μM), 
succinate (10 mM), antimycin A (5 μM), N,N,N',N'-tetramethyl-p-phenylenediamine 
(TMPD)/ascorbate (0.5mM/2mM), and finally cytochrome C (10 μM). At the end of each 
experiment the fiber bundles used were washed with distilled water and lyophilized in a freeze-
dryer (Labconco, Kansas city, MO) for 3 hours and then weighed on a microsclae (Mettler-
Toledo XS3DU).  O2 consumption is expressed in pmol/min*mg dry wt. 
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Cardiac mitochondria isolation 
Cardiac mitochondria were isolated from the LV following our established protocol [62], 
and all steps were performed at 4°C. Briefly, after rinsing the excised heart in ice-cold isolation 
solution (IS) containing 300mM sucrose, 10 mM sodium-hepes and 0.2 mM EDTA, pH 7.2, the 
LV was minced into small pieces, digested with trypsin (0.125mg/ml IS) for 2 minutes. The 
digestion was then stopped with soybean trypsin inhibitor (0.65 mg/ml IS) containing 1 mg/ml 
BSA. The buffer was removed, and the tissue resuspended in IS/BSA, and homogenized with a 
teflon Potter homogenizer. The homogenate was centrifuged at 600 x g for 10 min, and the 
resultant supernatant was centrifuged at 8,000 x g for 15 min. The supernatant was discarded, 
and the pellet re-suspended in IS/BSA. This step was repeated one more time, and the final pellet 
was resuspended in a small volume of IS, and kept on ice until use.  
Calcium uptake studies 
Quality of mitochondria was assessed by measuring their coupling state (measure of 
respiratory control ratio; RCR). State 2 (non-phosphorylating state) and state 3 (phosphorylating 
state) respiration were measured in buffer Z using the high resolution OROBOROS O2K 
oxygraph. The assays were conducted at 25°C under continuous stirring, and state 2 respiration 
was initiated by the addition of glutamate (10 mM) and malate (5mM). Once oxygen 
consumption reached a steady state, saturating level of ADP (2.5 mM) was added to initiate state 
3 respiration. The RCRs were calculated by dividing state 3 respiration by state 2 respiration. 
Mitochondrial Ca uptake studies were performed as described in Sloan et al. 2012 [62]. Briefly, 
0.75 mg mitochondrial protein were suspended in 2ml assay buffer (125mM KCl, 5mM HEPES, 
2mM KH2PO4, 1mM MgCl2, pH = 7.3) containing 1 μM of the fluorescent probe Ca green 5 N 
salt (506 and 532 nm excitation and emission wavelengths respectively), and extra-mitochondrial 
Ca fluorescence was monitored with a fluorescence spectrophotometer (Photon Technology 
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International, Birmingham, NJ, USA), following pulses of 50 nmoles CaCl2.  All uptake studies 
were performed under state 2 conditions (5 mM glutamate/5 mM malate), and time to 63% 
corresponded to the time it took the mitochondria to accumulate 63% of total Ca accumulated 
following 1 pulse of CaCl2. For experiments where redox state was manipulated, energized 
mitochondria were treated with 2 mM of the thiol reductant dithiothreitol (DTT) 10 min before 
initiating Ca pulses.  
Mitochondrial membrane potential measurement 
Mitochondrial membrane potential (ΔΨm) was determined using a method similar to that 
described by Kamo et al. [148]. Mitochondrial accumulation of the lipophilic cation, 
tetraphenylphosphonium (TPP
+
) was monitored with a TPP
+
 selective electrode and an Ag/AgCl 
reference electrode (World Precision Instruments, Sarasota, FL, USA) as changes in voltage. The 
latter was monitored on a Dell computer using commercially available software (Chart, AD 
Instruments, Colorado Springs, CO, USA). The ΔΨm was estimated from the equation: ΔΨm = 
58*log(v/V) – 58*log(10FΔE/2.3RT-1) [148], where ΔE is deflection in TPP+ voltage from baseline; 
R is gas constant; T is temperature; v is mitochondrial matrix volume, and V is buffer volume. 
The baseline voltage was taken before addition of substrates, and mitochondrial matrix volume 
was assumed to be of 1μl/mg protein [149]. Based on a previous study [150], we assumed that 
matrix volumes were similar between diabetic and non-diabetic rats. For ΔΨm experiments, both 
the TPP
+ 
selective electrode and the reference electrode were placed in a magnetically stirred 
chamber containing 2.5 ml mitochondria assay buffer (described above), 0.5 mg mitochondria, 
supplemented with 1.2 μM TPP+, and glutamate/malate (5 mM each). State 3 respiration was 
initiated with the addition of 2.5 mM ADP. 
Western Blot analysis 
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Cardiac LV mitochondria were isolated as described above, and protein content was 
determined using a BCA protein assay. Aliquots of LV mitochondria proteins were solubilized, 
subjected to SDS-PAGE and transferred to an Immobilon-P transfer membrane. After blocking 
in Tris-buffered saline containing 0.1% Tween (TBS-T) and 4% bovine serum albumin for 1 h at 
room temperature, the membrane was incubated with the mitochondrial Ca uniporter (MCU) 
antibody (1:1000; Santa Cruz), mitochondrial Ca uptake 1 (MICU1) antibody (1:1000, abcam), 
mitochondrial Ca uniporter regulator 1 (MCUR1) antibody (1:1000, Aviva Systems Biology), 
total OXPHOS cocktail antibody (1:500; MitoSciences), or VDAC (1:1000, abcam) overnight at 
4 °C. The membrane was washed with TBS-T and incubated with an IR-Dye-conjugated 
secondary antibody for 1 h at room temperature then washed again with TBS-T and finally with 
TBS. The immunoreactive bands were scanned and quantified using the Odyssey Infrared 
Imaging system and software, respectively (LI-COR Biosciences, Lincoln, NB). 
Statistical analysis 
Data are presented as mean ± SEM. Statistical analyses were performed using a two way 
or a one way ANOVA with Tukey’s multiple comparison post-hoc analysis. For all comparisons, 
the level of significance was established at P<0.05.  
Results 
Effect of Bendavia on morphological, metabolic and hemodynamic parameters in diabetic rats 
Morphological, metabolic and hemodynamic data are presented in Table 1. Animals in 
the STZ-saline group were hyperglycemic as expected, and showed a significant decrease in 
body and heart weights when compared to non-diabetic animals in the control-saline and control-
Bendavia groups (P<0.05). The decrease in heart weight was associated with a significant 
decrease in both LV and RV mass, and although the decrease was statistically significant when 
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normalized to body weight and in comparison to non-diabetic animals (P<0.05), this difference 
was no longer significant once normalized to tibia length (P>0.05). In the isolated perfused heart 
studies, the left ventricular developed pressure at baseline was not significantly different among 
groups. Acute treatment with Bendavia didn’t have any significant effect on the morphological 
parameters (P>0.05). 
Effect of Bendavia on cardiac bioenergetics  
In isolated perfused hearts  
Assessment of myocardial oxygen consumption in isolated hearts shows that diabetic 
hearts have a significantly decreased MVO2 at baseline, as well as in response to increased 
cardiac workloads (pacing at 5 Hz and 7 Hz), and that treatment with Bendavia significantly 
improves their MVO2 under all conditions as it is shown in STZ-Bendavia group (P<0.05; Fig. 
8A). Furthermore, the rate of increasing MVO2 in response to increased cardiac workloads is 
significantly slower in the diabetic hearts and is increased to control levels following treatment 
with Bendavia at 5Hz but not at 7 Hz (Fig. 8B and C).  
In skinned cardiac fibers 
Mitochondrial respiratory capacity was overall decreased in cardiac fibers from diabetic 
hearts, and improved following treatment with Bendavia. Under state 2 condition (no ADP), 
complex I-supported respiration was significantly decreased in diabetic cardiac fibers, and 
treatment with Bendavia restored it to control levels, as it is shown in STZ-Bendavia group 
(P<0.05; Fig. 8D). Under state 3 conditions (2.5 mM ADP), complex I-supported respiration 
was decreased in diabetic cardiac fibers even though it didn’t reach statistical significance, and 
was improved with Bendavia treatment (Fig. 8E). Under state 3 conditions, complex II-supported 
respiration was significantly decreased in diabetic cardiac fibers, and significantly improved by 
51 
 
the treatment with Bendavia (P<0.05; Fig. 8F). Complex IV-supported respiration in the 
presence of ADP was not significantly different among groups (data not shown).  
Effect of Bendavia on mitochondrial function  
Mitochondrial maximal respiratory capacity  
Maximal mitochondrial respiratory capacity, as assessed with the uncoupler FCCP in 
isolated perfused hearts, did not show any significant difference among groups (P>0.05; Table 
1). 
Mitochondrial Ca uptake 
Ca uptake was significantly slower in cardiac mitochondria from diabetic animals compared to 
mitochondria from control animals (P<0.05), and the treatment with Bendavia led to a 
significant increase in the ability of diabetic mitochondria to uptake Ca as illustrated in Fig. 9A 
(P>0.05; STZ-Bendavia group). Pre-treating cardiac mitochondria from diabetic hearts with the 
thiol-reducing agent DTT had a similar effect (P<0.05; Fig. 9B and C). 
Mitochondrial membrane potential 
Mitochondrial membrane potential, as assessed with TPP in isolated mitochondria, did 
not shown any significant difference among groups (P>0.05; Fig. 9D). 
Effect of Bendavia on the expression level of mitochondrial Ca handling proteins 
Mitochondria from diabetic hearts showed a significant decrease in the expression level 
of both MCU and its regulatory protein MCUR1, and treatment with Bendavia re-established the 
expression level of both proteins to control levels (Fig. 10A and C). The other regulatory protein 
of MCU (MICU1) was decreased following treatment of diabetic rats with Bendavia but this 
change did not reach a statistical significance (Fig. 10B). 
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Effect of Bendavia on the expression level of oxidative phosphorylation proteins 
Mitochondria from diabetic hearts showed a significant decrease in the expression level 
of both complex I and complex V, and the treatment with Bendavia re-established the expression 
level of both proteins to control levels (Fig. 11A and B respectively).  
Discussion 
The goal of this study was to determine if daily treatment with Bendavia, a novel 
mitochondria-targeting peptide, would improve cardiac bioenergetics and result in a better 
energy supply-demand matching in diabetic hearts. The major findings of this study are: First, 
treatment with Bendavia improved the ability of diabetic hearts to adjust quickly and efficiently 
to increased cardiac workload. Second, following treatment with Bendavia, mitochondrial 
dysfunction was ameliorated as manifested by a better ability to uptake Ca, and an enhanced 
respiratory capacity. Third, a reductive shift in redox state of diabetic heart mitochondria 
normalizes mitochondrial Ca. Finally, our data show that the effects of Bendavia are evident at 
the molecular and functional levels of mitochondrial Ca handling proteins as well as the 
oxidative phosphorylation machinery. 
Cardiac mitochondria from diabetic patients and diabetic animals have a reduced calcium 
uptake capacity, although the underlying reasons are not understood. Data presented herein 
implicate the expression of MCU and MCU-regulating proteins as contributors to lower 
mitochondrial calcium influx. Furthermore, our results show that by targeting the mitochondria 
we can improve mitochondrial Ca handling, defective cardiac bioenergetics, and the ability of 
the diabetic heart to increase its myocardial oxygen consumption and its bioenergetics to adjust 
to changing workloads. To the best of our knowledge, this study is the first to show that MCU, 
and MCU-regulating proteins are depressed in diabetic hearts, and that their expressions can be 
re-established to “healthy-state” levels by the mitochondria-targeting peptide Bendavia. Our 
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findings identify a new therapeutic target which modulation can contribute to ameliorating the 
energy supply-demand mismatching, a hallmark of diabetic cardiomyopathy, and a major 
contributing factor to heart failure, and high mortality rates in diabetic patients.  
Among the myriad of factors involved in the increased mortality rate associated with diabetic 
cardiomyopathy, recent evidence suggests that decrements in bioenergetic coordination are 
centrally involved. While the healthy heart is proficient at adjusting its energy supply to demand, 
the diabetic heart has a very limited capacity of energy matching [17, 18]. A growing body of 
literature indicates that alterations in mitochondrial function may be responsible for the increased 
cardiac dysfunction observed in diabetes (reviewed in [19]). Indeed, decreased cardiac 
mitochondria respiratory capacity has been reported in experimental models of type II diabetes 
such as db/db [151], and ob/ob mice [152], as well as in the STZ model of type I diabetes [57, 
58, 153, 154]. While our results are consistent with this literature, they do shed more light on key 
components of this mismatching between energy supply and demand in the diabetic heart. Our 
study is the first to link the decreased mitochondrial Ca uptake, in diabetic hearts, to a decreased 
expression of the pore forming protein of the mitochondrial Ca uniporter, MCU. Our data are 
supported by a recently published study using mice lacking MCU [56], where the authors show 
that in the absence of MCU, mitochondria from skeletal muscle showed slow calcium uptake, 
and have low levels of Ca in their matrix. This decrease in mitochondrial Ca, manifested by 
MCU deficient mice, correlated with higher pyruvate dehydrogenase (PDH) phosphorylation and 
lower PDH activity, and even though it did not affect the baseline whole body oxygen 
consumption, it did result in reduced performance in situations requiring high-energy 
expenditure such as the inclined treadmill, or pull-up tests [56]. These new findings confirm that 
in vivo, mitochondrial calcium uptake is important for muscle activity, particularly when 
workload is increased. Since excessive mitochondrial Ca uptake leads to permeability transition 
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pore (PTP) opening, and too little mitochondrial Ca compromises skeletal muscle as well as 
cardiac muscle bioenergetics, an effective therapeutic approach would be to stimulate MCU 
activity and effectively inhibit the PTP opening. We have shown that Bendavia does protect 
against ischemia/reperfusion injury by delaying redox-dependent PTP opening [62], and our data 
herein suggest that Bendavia ameliorates mitochondrial Ca uptake, under circumstances of 
increased demand, in a compromised diabetic myocardium.  
Our data further show that the expression level of MCUR1, which is essential for 
mitochondrial Ca uptake and the regulation of cellular metabolism [55], is also decreased in 
diabetic hearts. The expression level of both MCU and MCUR1 were increased to control levels 
following treatment with Bendavia, which suggest a new target for Bendavia and maybe a new 
mechanism of action by which this peptide might ameliorate the heart bioenergetics. Whether 
this effect is direct by an action on transcription factors or other pathways involved in the 
regulation of these proteins, or whether it is an indirect effect, resulting from a general decrease 
of ROS generation, remains to be determined.  
In the heart, mitochondrial Ca uptake by MCU only occurs when the cytosolic levels of Ca 
are high (during systole) which suggest that mitochondrial Ca levels in the mitochondrial matrix 
are kept low by a highly regulated process. Indeed, Mallilankaraman et al [54] identified MICU1 
as the gatekeeper for MCU-mediated Ca uptake. This protein is required to protect mitochondria 
from Ca overload; however, it does not affect the kinetics of MCU [54]. Diabetic hearts treated 
or not with Bendavia did not show a significant difference in MICU1 expression level.  
It is well documented that diabetic hearts exhibit oxidative stress due to an increased 
production of reactive oxygen species (ROS) [21, 155] and a decreased ROS buffering capacity 
[22, 24]. A consequence of this oxidative shift in redox-state is the oxidation of glutathione, the 
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major thiol buffering system.  This has been shown in human diabetic atrium [102], and animal 
models of diabetes [62, 79]. We have recently confirmed that while Bendavia had no direct 
scavenging capacity, it does limit the ability of isolated cardiac mitochondria to emit hydrogen 
peroxide (H2O2) [156]. Our results herein show a similar recovery of mitochondrial Ca uptake 
capability in both cardiac mitochondria from diabetic animals treated with Bendavia, and in 
cardiac diabetic mitochondria treated with DTT in vitro. These findings suggest that the 
improved mitochondrial Ca uptake seen in diabetics following treatment with Bendavia might be 
due, at least in part, to decreased mitochondrial ROS levels. This finding indicates that MCU 
activity is redox dependent. Further studies aiming to characterize the redox state of MCU in 
diabetic hearts are warranted to confirm this observation.    
High levels of ROS can affect multiple proteins by altering their activity and/or 
expression levels. Qin et al. [157] reported that post-translational oxidative modification of 
sarcoplasmic reticulum calcium ATPase (SERCA) led to a decrease in its activity and 
contributed to the impairment of relaxation. Others also reported the same finding for SERCA in 
myocardial ischemia/reperfusion injury [158]. We have shown, using the same experimental 
model of diabetes as the current, that increased propensity to PTP opening is associated with 
increased oxidative post-translational modification of the adenine nucleotide translocase [62]. 
So, therapeutic strategies that decrease oxidant levels and/or protect target proteins, such as 
MCU, from oxidation might be of value to preserve the cardiac function in diabetic patients.  
The fact that Bendavia improves Ca uptake in cardiac diabetic mitochondria, and results 
in the recovery of MCU expression levels suggests that this mitochondria-targeting peptide 
might regulate both the activity and the expression of MCU. This double action might be 
indirectly mediated by a reduction in ROS levels or, it might be due to a yet unknown 
mechanism of action of this peptide.  
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A direct consequence of an improved mitochondrial Ca uptake is a better capacity to 
generate ATP to match the cardiac myocyte needs. Indeed, it is well recognized that 
mitochondrial Ca fluxes are integral to ATP supply and demand matching (reviewed in [10]). Ca 
serves as a key activator of several Krebs cycle dehydrogenases such as PDH, glycerol 3-
phosphate dehydrogenase, NADH-linked isocitrate dehydrogenase, and α-ketoglutarate 
dehydrogenase, as well as the ATP-synthase [51, 159-161]. Consistent with the relationship 
between mitochondrial Ca and oxidative phosphorylation capacity, our results show an 
improvement of mitochondrial respiratory capacity with different substrates under 
phosphorylating state, and this is concomitant with an increase in the expression level of 
complex I and V of the mitochondrial respiratory chain. This suggest that treatment with 
Bendavia results in an improvement of the cardiac mitochondrial function that might be 
explained by a dual improvement of the expression and activity of mitochondrial proteins 
involved in Ca uptake and oxidative phosphorylation. This finding is also supported by the 
correlation between decreased PDH activity and the lack of MCU shown by Pan et al in MCU 
deficient mice [56]. 
One limitation to our study is the use of type I diabetes animal model (streptozotocin-
induced diabetes) instead of a type II diabetes model. The most common form of diabetes is 
diabetes mellitus type II, but both types of diabetes show similarities as reported in clinical and 
experimental studies. Just like cardiac mitochondria from animals with type II diabetes, 
mitochondria from hearts of type 1 diabetic animals exhibit reduced oxidative phosphorylation 
capacity, a lower ATP synthase activity, [57], a decreased mitochondrial calcium uptake [58, 62, 
69], and an increased oxidative stress burden [24].  
Cardiovascular disease remains the leading cause of mortality and morbidity in 
individuals with diabetes. This cardiovascular-associated mortality is believed to be mainly a 
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consequence of coronary artery disease. However, compelling epidemiological and clinical data 
indicate that diabetes increases the risk for cardiac dysfunction and heart failure independently of 
other risk factors such as coronary disease and hypertension, as firstly reported by Rubler in 
1972 [162]. Furthermore, mounting data point to mitochondrial dysfunction as being a major 
early contributor to diabetic cardiomyopathy. It is then, critical to develop therapeutic strategies 
targeting mitochondria to correct, and maybe prevent early defects in cardiac mitochondrial 
function in order to prevent the myocardial bioenergetic defects from leading to heart failure. 
In conclusion, our study aimed to understanding how Bendavia improves bioenergetics in 
diabetic hearts. This study provides novel evidence that this mitochondria-targeted peptide is a 
plausible and promising candidate for the reduction of diabetic cardiomyopathy in its early 
stages, by correcting mitochondrial dysfunction at different levels.  
 
58 
 
Table 4  
Morphological, metabolic and hemodynamic data from control and diabetic rats treated with 
Bendavia (1.5 mg Kg
-1
 day
-1
) or vehicle (saline) 
Parameters 
Control-
Saline 
(n=6) 
Control-Bendavia 
(n=6) 
STZ-Saline 
(n=13) 
STZ-Bendavia 
(n=13) 
Body weight (g) 361 ± 12 372 ± 6 225 ± 6 *# 250 ± 14 *# 
Heart weight (g) 1.44 ± 0.13 1.42 ± 0.07 1.08 ± 0.05 *# 1.06 ± 0.06 *# 
LV weight (g) 0.81 ± 0.07 0.87 ± 0.04 0.61 ± 0.03 *# 0.62 ± 0.04 *# 
RV weight (g) 0.20 ± 0.01 0.21 ± 0.01 0.14 ± 0.01 *# 0.15 ± 0.01 *# 
HW/TL 37 ± 4 40 ± 2 33 ± 2  31 ± 2  
HW/BW 3.60 ± 0. 31 3.82 ± 0.23 4.81 ± 0.19 *# 4.28 ± 0.23  
Fasting blood glucose 
(mg/dl) 
112 ± 4 144 ± 10 488 ± 24 *# 
467 ± 44 
*# 
MVO2 max 
(µmole/min*g dry HW) 
69 ± 
6 
65 ± 2 63 ± 6  85 ± 6  
LVDP (mmHg) 
143 ± 
11 
118 ± 9 
122 ± 
12  
95 ± 14  
 
Results are expressed as means ± SEM (n= 6-13 rats per group).  
STZ, streptozotocin; LV, left ventricle; RV, right ventricle; HW, heart weight; TL, tibia length ; 
BW, body weight, MVO2max, maximal myocardial oxygen consumption following injection of 
the uncoupler; FCCP, LVDP, left ventricular developed pressure at baseline. Statistical 
significance: * P<0.05 vs. Control-Saline group # P<0.05 vs. Control-Bendavia group.  
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Figure 8 (cont’d) 
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Figure 8 (cont’d) 
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Figure 8 (cont’d) 
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Figure 8 (cont’d) 
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Figure 8 (cont’d) 
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Figure 8: Diabetic animals display a decreased cardiac and mitochondrial oxygen consumption 
that were restored following treatment with Bendavia. Myocardial oxygen consumption (MVO2) 
in control and diabetic rats treated with vehicle or Bendavia (1.5 mg/Kg for 4 days) was 
measured in perfused hearts at baseline, and after increasing cardiac workload by pacing the 
hearts continuously at 5Hz then 7 Hz for 3 minutes each time (A). The ability of control and 
diabetic hearts to adjust their oxygen consumption to the increased workload was assessed in 
isolated perfused hearts by measuring the change in myocardial oxygen consumption (Delta 
MVO2, which corresponds to change in MVO2 from baseline level to level immediately 
following pacing) with changing workloads at 5Hz (B) and 7 Hz (C). Complex I-supported-
respiration was measured in skinned cardiac fibers from control and diabetic animals using 
glutamate and malate as substrates, in the absence (D), and the presence (E) of ADP. Complex II 
supported-respiration was assessed in the presence of rotenone and ADP using succinate as 
substrate (F). Data are means ± SEM of 6-8. Statistical significance: *P<0.05 vs. Control-saline 
group; #P<0.05 vs. Control-Bendavia group; ΔP<0.05 vs. STZ-saline group. 
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Figure 9 
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Figure 9 (cont’d) 
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Figure 9: Diabetic animals display a decreased cardiac mitochondrial function that was 
improved following treatment with Bendavia. All experiments were conducted in control and 
diabetic rats treated with vehicle or Bendavia (1.5 mg/Kg for 4 days). Mitochondrial Ca uptake 
was measured in isolated cardiac mitochondria using a Ca-sensing probe (calcium green-5N 
salt), and the time it took mitochondria to accumulate 63% of total Ca following one pulse of 
CaCl2 was determined in non-pretreated mitochondria (A) or DTT-pretreated mitochondria (C). 
Representative trace of Ca uptake is displayed in B. Mitochondrial membrane potential was 
measured in isolated cardiac mitochondria using an electrode sensitive to TPP under state 2 (no 
ADP) and state 3 (2.5 mM APD) respirations (D). Data are means ± SEM of 6-8. Statistical 
significance: *P<0.05 vs. Control-saline group; #P<0.05 vs. Control-Bendavia group; ΔP<0.05 
vs. STZ-saline group. 
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Figure 10 
A. 
 
 
 
 
 
 
 
 
MCU 
VDAC 
M
C
U
 l
e
v
e
ls
(n
o
r
m
a
li
z
e
d
 t
o
 V
D
A
C
)
0
1
2
3
* #
C o n tro l
S a lin e
S T Z
S a lin e
C o n tro l
B e n d a v ia
S T Z
B e n d a v ia

Control 
Saline 
STZ 
Saline 
Control 
Bendavia 
STZ 
Bendavia 
50KDa 
68 
 
Figure 10 (cont’d) 
B. 
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Figure 10 (cont’d) 
C. 
 
 
Figure 10: Diabetic animals display a decreased expression of mitochondrial Ca handling 
proteins which was improved following treatment with Bendavia. Western blots of mitochondrial 
Ca handling proteins as assessed in cardiac mitochondrial extracts. A: MCU, B: MICU1, and C: 
MCUR1. Quantitative analyses are reported in the histograms, and they represent the expression 
level (band densitometry) of each protein normalized to the mitochondrial protein VDAC. Data 
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are means ± SEM of 3. Statistical significance: *P<0.05 vs. Control-saline group; #P<0.05 vs. 
Control-Bendavia group; ΔP<0.05 vs. STZ-saline group. 
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Figure 11 
A. 
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Figure 11 (cont’d) 
B. 
 
Figure 11: Diabetic animals display a decreased expression of oxidative phosphorylation 
proteins which was improved following treatment with Bendavia. Western blots of mitochondrial 
respiratory complexes as assessed in cardiac mitochondrial extracts. A: Complex I and B: 
Complex V (F1/Fo-ATPase). Quantitative analyses are reported in the histograms, and they 
represent the expression level (band densitometry) of each protein normalized to the 
mitochondrial protein VDAC. Data are means ± SEM of 3. Statistical significance: *P<0.05 vs. 
Control-saline group; #P<0.05 vs. STZ-saline group.  
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Chapter 4: Macromolecular organization of the mitochondrial respiratory complexes 
following myocardial ischemia reperfusion injury, and its impact on mitochondrial 
function 
 
Introduction 
Dysfunction of the mitochondrial respiratory complexes (MRCs) are highly associated 
with the decline in mitochondrial bioenergetics, and this decline is a major contributor to 
myocardial injury resulting from ischemia/reperfusion (IRI) [8, 163-166].  
The direct consequence of IR-induced structural alterations of the MRCs is inefficient 
electron transfer.  The latter results in secondary electron leak leading to increased ROS 
generation [166-168]. Furthermore, IRI is also associated with a decrease in the ROS buffering 
capacity. For instance, the myocardial glutathione system, which is a major cardiac antioxidant 
[101], shows a significant decline in its ROS buffering ability following IRI as reflected by a 
decrease in the glutathione redox couple (GSH/GSSG) as we [62, 84], and others [169] have 
shown in rodent hearts. Thus, the increase in ROS generation coupled with reduced antioxidant 
capacity leads to a net accumulation of ROS. These highly reactive molecules can interact with 
the mitochondrial proteins and lipids and initiate their oxidative modification. Indeed, oxidation 
of multiple subunits of complex I [169, 170], and complex II [169, 171] was reported after 
cardiac IRI. When MRC proteins are the target of this oxidative modification, they show 
structural and functional changes leading to an overall decline in mitochondrial bioenergetics 
[172, 173].  
Recent evidence, based on the separation of MRCs by BN-PAGE, suggests that they can 
be organized in supramolecular assemblies called supercomplexes or respirasomes [31, 36-38]. 
This organization has functional features because higher rates of respiration are achieved when 
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the MRCs are agglomerated into supercomplexes. The reason for this higher mitochondrial 
efficiency is believed to be granted by the optimal vicinity between different redox partners 
resulting in substrate channeling, a more efficient electron transfer, and less electron loss 
(reviewed in [45]). The supercomplexes are mostly the result of the association between 
complexes I, III, and IV at different stoichiometries depending on the organism and the organ 
studied.   
The levels of supercomplexes were reported to be decreased in a canine model of heart 
failure [174]. This decrease in the amount of respirasomes was accompanied by a significant loss 
of efficient electron transfer in subsarcolemmal and intrafibrillar cardiac mitochondria, 
indicating an association between the supramolecular organization of the MRCs and the 
mitochondrial function.  In addition, the integrity as well as the stochiometry of different MRCs 
is essential to the formation and stability of the supercomplexes [29]. Indeed, in Barth syndrome 
and Leigh syndrome where complex I and complex III structures are altered, the assembly of 
supercomplexes is also altered and is associated with a decreased mitochondrial function.  
In chapters 2 and 3, we used well established experimental models of diabetes and IRI in 
order to gain insight into the mechanisms behind the aberrant cardiac bioenergetics associated 
with these two disease states. We showed significant molecular changes of multiple 
mitochondrial proteins (mitochondrial Ca-handling proteins and multiple respiratory complexes). 
These molecular changes were associated with mitochondrial and cardiac dysfunctions, both of 
which were improved in presence of the protective inner mitochondrial membrane-targeting 
peptide, Bendavia. So, in this chapter we investigated the impact of the MRCs molecular 
organization on cardiac bioenergetics following IRI. We assessed the correlation between the 
respiratory rate and the profile as well as the content of mitochondrial supercomplexes (supra-
molecular organization of MRCs). We utilized Bendavia [2] for its established protective effects 
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against IRI [175-177] and looked at its effect on the content and integrity of mitochondrial 
supercomplexes in the post-ischemic heart. 
Methods 
Animals  
Male Sprague-Dawley rats (aged 2-3 months) were used in the study.  All procedures 
received prior approval from the East Carolina University Institutional Animal Care and Use 
Committee.  Animals were housed in a temperature and light-controlled environment and 
received food and water ad libitum.  Animals received an i.p. injection of a ketamine/xylazine 
(90mg/kg/10mg/kg, respectively), and hearts were excised after the diminution of animal 
reflexes, via midline thoracotomy and placed in ice-cold saline. Excised hearts were perfused on 
our modified Langendorff apparatus per our established protocols [87, 90]. Hearts were exposed 
to 20/120 minutes of global ischemia/reperfusion.  For the Bendavia treatment, hearts received 
1nM Bendavia beginning at the onset of reperfusion, which is a well-established cardioprotective 
paradigm in our models [175, 177]. At the end of reperfusion, hearts were split into the 
experimental groups described below. 
Separation of native mitochondrial respiratory chain complexes by BN-PAGE  
 Separation of mitochondrial supercomplexes was performed using BN-PAGE according 
to methods described by Schägger et al. [36]. Mitochondrial membranes were solubilized using 
either digitonin (digitonin: mitochondrial protein ratio was 8:1 (w/w)) or n-dodecyl-β-D 
maltoside (DDM:protein ratio of 2:1) in a buffer containing 6N HCl, 50 mM NaCl, 0.001% 
Ponceau S, and 50 mM Bis-Tris, pH 7.2. After solubilization, the samples were centrifuged for 
30 min at 20, 000 x g, and protein content of the supernatant was determined using bicinchoninic 
acid (BCA protein assay reagent, Thermo Scientific, Rockford, IL, USA). Coomassie G-250 was 
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added to each sample in a ratio detergent-to-dye of 8:1 (w/w), and 35 µg total proteins from each 
sample were separated on a Native PAGE 3-12% Bis-Tris (Life Technologies, Carlsbad, CA, 
USA) at 4°C. Running buffer was supplemented with 0.02% Coomassie G-250 to allow 
visualization of protein bands. The stained bands were scanned using the Odyssey Infrared 
Imaging system (LI-COR Biosciences, Lincoln, NB), and the densitometric analysis was done 
using Image J software (National Institutes of Health).  
High-resolution respirometry.  
Following the I/R injury, the left ventricle was dissected and placed on a petri dish 
containing ice-cold buffer X containing in (mM): 7.23 K2EGTA, 2.77 CaK2EGTA, 20 
Imidazole, 20 Taurine, 5.7 ATP, 14.3 Phosphocreatine, 6.56 MgCl2-6H2O and 50 MES; pH 7.1. 
All fat and connective tissue was removed under a dissecting microscope, and small cardiac fiber 
bundles (5-7 mg of wet weight) were prepared. Fiber bundles were permeabilized using 50μg/ml 
saponin at 4°C for 20 min. Permeabilized fiber bundles were then washed, 3 times for 5 min 
each, in ice-cold buffer Z containing in (mM): 110 K-MES, 35 KCL, 1 EGTA, 5 K2HPO4, 3 
MgCl2-6H2O, and 5 mg/ml BSA; pH 7.4. The fiber bundles were kept at 4°C in buffer Z until 
analysis. 
All experiments were conducted at 37°C in presence of 20 μM blebbistatin to prevent 
contraction. We used the Oroboros system (Oroboros Instruments, Innsbruck, Austria) to 
measure O2 consumption per our established protocols [146]. Buffer Z was used as respiration 
medium and O2 consumption was monitored during a substrate-inhibitor titration oxygraphic 
protocol in order to obtain a step-by-step analysis of various components of the mitochondrial 
respiratory chain as described by Kuznestov et al. [147]. The addition of substrates and inhibitors 
was done in the following sequence: glutamate/malate (10mM/5mM), ADP (2 mM), rotenone 
(0.5 μM), succinate (10 mM), antimycin A (5 μM), N,N,N',N'-tetramethyl-p-phenylenediamine 
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(TMPD)/ascorbate (0.5mM/2mM), cytochrome C (10 μM), and FCCP (1 μM). At the end of 
each experiment the fiber bundles used were washed with distilled water and lyophilized in a 
freeze-dryer (Labconco, Kansas city, MO) for 3 hours and then weighed on a microsclae 
(Mettler-Toledo XS3DU).  O2 consumption is expressed in pmol/min*mg dry wt. FCCP data 
were excluded from 3 fibers because they were statistical outliers, with values > 2 standard 
deviations away from the group mean.   
Statistical analyses. 
All data were analyzed using and GraphPad Prism and are presented as mean ± SEM. We 
ensured the data were distributed normally, which allowed for parametric analyses. Statistical 
analyses were conducted using a one-way ANOVA, with p values < 0.05 considered significant. 
To conduct statistical analyses with fluorescence studies, the percent change were calculated 
based on the maximal fluorescence value for fluorescence emission.  
Results 
Blue-native PAGE studies.   
Blue-native gels are presented in Fig. 12. The density of mitochondrial supercomplexes 
was significantly lower following ischemia-reperfusion, and post-ischemic administration of 
Bendavia significantly improved the formation of respiratory supercomplexes (Fig. 12A; 
P<0.05).  The expression of native complex I was higher in the ischemia-reperfusion group, and 
normalized with Bendavia perfusion (Fig. 12B and C).  Native Complex V expression was 
significantly depressed with ischemia-reperfusion, and brought back to control levels with 
Bendavia treatment (Fig. 12B and D). There were no differences in endogenous complex III2 
expression among groups in the study (Fig. 12E). Interestingly, we observed the presence of 
‘breakdown’ products in the ischemia-reperfusion group, with the most prominent molecular 
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weights being between 400-500kDa. Post-ischemic treatment with Bendavia significantly 
attenuated the presence of these ‘degradation’ bands (Fig. 12F; P<0.05).   
High-resolution respirometry in permeabilized ventricular fibers.  
Respiratory control ratios (during glutamate/malate-stimulated respiration) were 3.6 ± 0.2 
in control fibers.  As expected, the respiratory control ratio decreased after ischemia-reperfusion 
(1.9 ± 0.1; P<0.05 versus control), and this drop was blunted in the ischemia-reperfusion + 
Bendavia group (2.5 ± 0.1; P<0.05 versus both ischemia-reperfusion and control).  We employed 
a substrate-inhibitor titration protocol to ascertain how each component of the electron transport 
chain was influenced by ischemia-reperfusion.  Respirometry data are presented in Fig. 13. 
States 3 and 4 respiration were significantly lower in the ischemia-reperfusion group, and this 
decline was partially reversed with Bendavia across groups, regardless of whether the 
mitochondria were respiring on glutamate/malate or succinate/rotenone (Fig. 13A and B). Both 
complex IV-dependent and FCCP-induced respiration were decreased following ischemia-
reperfusion, and Bendavia had no statistically significant effect in these studies (Fig. 13C and D).  
Discussion 
The main findings of our study are that IRI causes a significant decrease in mitochondria 
bioenergetics, considerable molecular changes of the individual respiratory complexes as well as 
their organization into supercomplexes and that the application of Bendavia at reperfusion is able 
to protect the mitochondria of ischemic hearts against all these structural and functional decays.  
Specifically, our data show a significant decrease in the content of supercomplexes, a loss 
of complex I integrity (appearance of degradation bands), and a significant decrease in the levels 
of complex V. The loss of complex I integrity is indicated by a combined decrease in its 
molecular weight, the appearance of small molecular weight bands, and a reduced efficiency in 
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electron transfer; all of which suggest complex I instability and possible degradation. This 
degradation is consistent with data in the literature showing an association between a decline in 
supercomplex content and the loss of both the integrity (loss of subunits) and the content of 
complex I. Since both normal expression of each individual respiratory complex, and sufficient 
quantities of the assembled supercomplexes are crucial for the mitochondrial function [178], our 
study identifies mitochondria-targeting peptide Bendavia as a suitable pharmacological approach 
to preserving mitochondrial bioenergetics by preserving the MRCs under individual and  
supercomplex forms.  
Following IRI, complex I is described to be in its deactivated form (there are 2 forms; A, 
active and D, deactivated) [166]. When in its D form, complex I can receive electrons from 
NADH but can’t deliver them to ubiquinon, so electrons leak generating ROS instead [166].  In 
the latter study, complex I oxidative capacity and its enzymatic activity were decreased and ROS 
generation was increased. Similar findings were reported by multiple studies showing a decline 
in complex I catalytic activity following IRI [166, 179-181]. In addition, pharmacological 
interventions aiming to inhibit complex I, during early reperfusion, protected mitochondria and 
heart tissue from ischemic injury and enhanced cardiac functional recovery [182-185]. In the 
study by Lesnefsky et al. (2004), the improved cardiac function was associated with a decrease 
in ROS generation by complex I, a prevention of cardiolipin loss, and an improved oxidative 
capacity of cytochrome c oxidase [182]. Interestingly, the assembly of MRCs, into 
supercomplexes stabilizes CI [186] and minimizes its ability to generate ROS [30]. Taken 
together these data suggest that following IRI, complex I structure and activity are altered 
leading to an overall decrease in its oxidative capacity and an increase in its ability to generate 
ROS, and that these changes might be related to the inability of complex I to integrate the 
supercomplex assembly.  
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Our data are consistent with the molecular changes of complex I, and its decreased 
oxidative capacity reported in the literature in the context of myocardial IRI. In addition, our data 
show that under native conditions, complex I of control hearts is mostly incorporated into 
supercomplexes, and this is coupled with a superior mitochondrial function. Again, this is 
consistent with the proposed role of supercomplex organization as it confers stability and 
efficiency to complex I (reviewed [45]). We also show that the inner mitochondrial membrane-
targeting peptide Bendavia is able to protect complex I from these molecular and functional 
alterations since its integrity and oxidative capacity are preserved in the presence of Bendavia. 
A number of human genetic disorders, caused by a single mutation, lead to deficiencies in 
more than one respiratory complex [187-189]. Such defects stem from the interdependence 
between the different MRCs and from the fact that their stability is dependent on their assembly 
into supercomplexes. In fact, the structural integrity of individual MRCs and their number in 
relation to each other (specific stoichiometry) are essential to their assembly into 
supercomplexes, which in turn  is required for the assembly, stability and catalytic efficiency of 
individual respiratory complexes [38, 188]. For instance, genetic mutations leading to defects in 
the assembly of complex III are associated with a decrease in the expression level, the activity 
and the incorporation of complex I into supercomplexes [38]. This relationship was shown in 
mouse and human-derived cultured cells as well as in muscle biopsies from patients with the 
same type of mutation. This finding was confirmed by another group while investigating the 
structural and functional consequences of the loss of complex IV and complex III on the 
composition and integrity of supercomplexes [188]. Using skeletal muscle biopsies from patients 
with Leigh syndrome (deficiency of complex IV), and patients with cytochrome b mutations 
(deficiency of complex III), Schagger and colleagues showed that while the loss of complex IV 
didn’t seem to affect the levels of complex I, that of complex III prevented the formation of 
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supercmplexes and resulted in a secondary loss of complex I. Similar association between 
complex IV/complex III and complex I was also shown in bacteria (Paracoccus denitrificans) 
[190]. Taken together, these results suggest that complex I assembly and activity are dependent 
on its integration into supercomplexes which in turn is dependent on the integrity of other MRCs 
such as complex III. This relationship between supercomplexes content and free complexes 
assembly and integrity could explain the results we see in IRI. We have a decrease in 
supercomplexes content and signs of degradation of complex I. Indeed the molecular weight of 
complex I is decreased in IRI group and new bands of lower molecular weight appear. This 
suggests that when complex I is not integrated into the supercomplex assembly it is either 
degraded or its structure is modified and this is consistent with the literature.  
Further studies are warranted in order to determine the composition of the 
supercomplexes as well as the degradation bands.   
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Figure 12 
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Figure 12 (cont’d) 
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Figure 12 (cont’d) 
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Figure 12 (cont’d) 
 
F.  
 
 
 
 
 
 
Figure 12. Blue-native gels for hearts in the study.  A. Mitochondrial respiratory 
supercomplexes following ischemia-reperfusion. B. Representative BN-PAGE gel for various 
native electron transport system complexes. Quantification of native complex I (C), V (D), III2 
(E), and degradation bands (F) from hearts in the study.  *, P<0.05. 
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Figure 13 
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Figure 13 (cont’d) 
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Figure 13. Site-specific changes in respiration following ischemia-reperfusion in permeabilized 
ventricular fibers.  We employed a substrate-inhibitor titration protocol to assess mitochondrial 
88 
 
complex-dependent respiration. A. Rates of State 4 (uncoupled) respiration in hearts from the 
study (glutamate/malate substrate).  B. State 3 respiration using either glutamate/malate or 
rotenone/succinate from hearts in the study.  C. Respiratory rates for fibers using complex IV-
dependent substrates.  D. Maximal FCCP-induced respiration for ventricular fibers in the study.  
*, P<0.05 versus control; #, P<0.05 versus ischemia-reperfusion untreated.   
  
 
 
Chapter 5: Integrated discussion 
The work presented in this dissertation advances our understanding of the molecular basis 
of impaired cardiac function in two conditions: Diabetes and ischemia/reperfusion injury. We 
link decrements in mitochondrial bioenergetics of diabetic and ischemic hearts, to molecular and 
structural changes of key components in the energy-transducing inner mitochondrial membrane. 
Specifically, our studies uncover some of the molecular mechanisms that contribute to increased 
susceptibility to IRI (diabetic hearts) and to cardiac inefficiency (diabetic and post-ischemic 
hearts). 
 Our data, presented in chapter 2, show that the increased ischemic injury in diabetic 
hearts was associated with an enhanced susceptibility to PTP opening which was favored by an 
oxidative burden. We confirmed this oxidative burden by measuring the myocardial redox 
couple of glutathione (GSH/GSSG) which was significantly decreased in diabetic hearts 
compared to non-diabetic ones. In order to establish a relationship between the increased 
oxidative shift in the cellular redox state and the enhanced propensity to PTP opening in diabetic 
hearts, we used a combination of free thiols-labeling and immuno-precipitation of the PTP-
regulatory protein, ANT. We were able to show that diabetic hearts had significant amounts of 
ANT that underwent post-translational oxidative modification, supporting the link between the 
oxidative shift in the redox state and the enhanced sensitivity to PTP-opening. Furthermore, our 
in vitro investigations of PTP opening under different redox states confirmed the redox-
regulation of PTP opening. Indeed, we were able to delay PTP opening in diabetic mitochondria 
by shifting the redox state to a more reduced one by either using a reducing agent (DTT, in vitro) 
or the ROS-reducing peptide, Bendavia (in vitro and in vivo). In addition, our results from whole 
heart studies further confirmed the above findings and allowed us to link the increased ischemic 
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injury in diabetic hearts to PTP-opening. We were able to reduce the myocardial injury, as 
measured by infarct size, by inhibiting PTP opening either directly or indirectly. Indeed, we 
inhibited PTP opening at reperfusion using three different molecules: NIM811 (inhibit 
cyclophilin D, component of PTP), minocycline (inhibits MCU and reduces Ca overload that 
contributes to PTP opening) and Bendavia (reduces ROS generation that also contributes to PTP 
opening). All three approaches brought the infarct size in diabetic hearts to levels similar to those 
of non-diabetic hearts, suggesting that PTP opening is a major pathological factor in the 
enhanced susceptibility of diabetic hearts to IRI. Thus, our results presented in chapter 2 provide 
a mechanism for the increased susceptibility of diabetic hearts to IRI and most importantly, they 
show that this susceptibility can be overcome by targeting the mitochondria and inhibiting either 
one of the three major pathological factors (Ca overload, ROS or PTP opening).   
Multiple studies have reported that diabetic cardiac mitochondria have a reduced capacity 
to accumulate Ca [58, 59, 69] and our data, presented in chapter 2, is in agreement with these 
reports. The fact that diabetic mitochondria have an enhanced sensitivity to PTP opening coupled 
with a reduced ability to accumulate Ca led Oliveira and colleagues [69] to conclude that this 
reduced capacity of mitochondrial Ca accumulation is the result of a defense mechanism rather 
than the result of defects in Ca uptake machinery [69]. However, Tanaka and colleagues [58] 
characterized the kinetics of mitochondrial Ca uptake and showed that diabetic cardiac 
mitochondria accumulated Ca at a slower rate and to a lower maximal extent suggesting that the 
machinery responsible for Ca uptake is altered by diabetes. Taking these results into 
consideration we hypothesized that the decreased ability of diabetic mitochondria to accumulate 
Ca is the result of molecular alterations of Ca uptake machinery (MCU complex). In addition, 
given the important role of Ca in the regulation of cardiac energy supply-demand matching, we 
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further hypothesized that these molecular alterations at the level of the MCU complex, if they 
exist, might explain the known mismatch between energy supply and demand in diabetic hearts.  
We first wanted to establish the energy supply-demand mismatching in diabetic hearts by 
evaluating myocardial oxygen consumption (index of ATP generation) under different workload 
conditions. Our results in the Langendorff system presented in chapter 3 show that myocardial 
oxygen consumption was significantly decreased in diabetic hearts at baseline. Moreover, when 
we increased cardiac workload by pacing the hearts, the diabetic hearts were slower at adjusting 
their oxygen consumption to the changing demand and were unable to further increase their 
oxygen consumption to match higher workloads. These data might be explained by a slower 
mitochondrial Ca uptake that does not allow diabetic hearts to rapidly signal their energy needs 
to mitochondria, resulting in a limited capacity of energy matching. These data are in agreement 
with those reported for mice lacking MCU that exhibit a marked impairment in their ability to 
perform strenuous work [56].  
In order to determine if there was an association between this energy supply-demand 
mismatching and mitochondrial Ca handling machinery, we next looked at MCU complex 
expression. Our data, presented in chapter 3, show a significant decrease in the expression levels 
of MCU and its regulatory protein MCUR1. The decrease in MCU could explain the inability of 
diabetic mitochondria to accumulate Ca to levels similar to those of healthy mitochondria. This 
is likely true, especially in the light of new evidence on the importance of MCU in mitochondrial 
Ca uptake that was provided by the use of transgenic mice lacking MCU [56].  Indeed, data 
reported in the study by Pan and colleagues [56] show that mice lacking MCU are unable to 
rapidly uptake Ca, compared to animals with intact MCU. Furthermore, our results also show a 
significant decrease in MCUR1, a protein that was recently reported to be essential for 
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mitochondrial Ca uptake and which ablation leads to the disruption of oxidative phosphorylation 
resulting in lower ATP levels [55]. These alterations of MCU and MCUR1 could explain, at least 
in part, the decline in mitochondrial Ca uptake by diabetic cardiac mitochondria and the directly 
related energy-supply demand mismatching seen in diabetic hearts.  
We further characterized the bioenergetics of diabetic hearts by assessing the 
mitochondrial function in permeabilized cardiac fiber bundles using high resolution 
respirometry. Our results (chapter 3) show that complex I- and complex II-supported respirations 
were decreased in diabetic mitochondria under non-phosphorylating (complex I) and 
phosphorylating conditions (complexes I and II). In addition, the decrease in complex I-
supported respiration was concomitant with a decrease in complex I subunit NDUFB8 as tested 
by western blot. We also found a significant decrease in the expression level of the ATP-
synthase (complex V) in diabetic hearts. The latter can be another contributing factor to the 
energy supply-demand mismatching of diabetic hearts. 
Taken together, these molecular changes, coupled with the functional defects that we 
showed in whole heart and permeabilized cardiac fiber bundles studies, provide a plausible 
mechanistic explanation for the decline in mitochondrial Ca uptake as well as the inefficient 
energy supply-demand matching in diabetic hearts. 
Recent experimental evidence supports the idea that mitochondrial respiratory complexes 
(MRCs) are assembled into supramolecular organizations called supercomplexes or 
respirasomes. These assemblies are proposed to be the ultimate structural model for an efficient 
electron transfer between the redox components of the MRCs leading to an optimal energy 
generation and limiting electrons leak and ROS generation (reviewed in [45]). Since the focus of 
the work presented in this dissertation was to understand the molecular defects leading to supply-
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demand mismatching in cardiac bioenergetics, whether it was caused by diabetes or IRI, we 
wanted to further characterize these defects in cardiac bioenergetics by looking at another level 
of organization of the MRCs: Supercomlexes. By focusing on the post-ischemic heart, we 
implemented and optimized the BN-PAGE approach to look at the expression of supercomplexes 
in mitochondria isolated from healthy and ischemic hearts. We performed these molecular 
analyses along with functional assessments of the cardiac mitochondria in permeabilized fiber 
bundles. We employed a substrate-inhibitor titration protocol to establish how each component 
of the ETC was influenced by ischemia-reperfusion. Our results, presented in chapter 4, show 
that ischemia-reperfusion led to a significant decrease in the overall mitochondrial function 
(complexes I-, II- and IV-supported respirations were decreased) with a pronounced reduction in 
supercomplex content. Furthermore, the decrease in supercomplex content in diabetic hearts was 
concomitant with three noteworthy changes. The latter were observed when mitochondrial 
membranes were solubilized using a stronger detergent (DDM) that breaks protein-protein 
interactions and separate the MRCs into free complexes.  Those three major changes were: 1) 
increase levels of the free form of complex I, 2) apparition of small molecular weight bands that 
might be degradation products and 3) a significant decrease in complex V (ATP synthase) 
content. It has been shown that complex I is unstable [186] and can undergo degradation [188] 
when it is not integrated into the supercomplex assemblies. This could explain the apparition of 
degradation bands but does not explain the increased levels of complex I. A more quantitative 
approach such as mass spectrometry should be applied in order to understand this discrepancy.  
Taken together these data suggest that following IRI, the structure (native gel data) and 
activity (respirometry data) of complex I are altered leading to an overall decrease in its 
oxidative capacity. These changes in complex I might be due to its non-optimal integration into 
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supercomplexes. Further analysis of the composition of supercomplexes is warranted in order to 
confirm this relationship that we are proposing.  
We have shown in chapter 2 that targeting the mitochondria at reperfusion can confer 
cardioprotection. This led us to further investigate the effect of Bendavia on mitochondrial 
bioenergetics of diabetic and ischemic hearts. In diabetic hearts (chapter 3), this mitochondria-
targeting peptide was able to improve myocardial oxygen consumption (at baseline and at lower 
workloads), to preserve mitochondrial Ca handling proteins (MCU and MCUR1) as well as 
complex I and ATP-synthase. These molecular effects were in agreement with the functional 
(respirometry studies) effects of Bendavia. In ischemic hearts (chapter 4), administration of 
Bendavia at reperfusion preserved supercomplexes and ATP-synthase contents. Furthermore, the 
hearts treated with Bendavia showed a higher recovery of mitochondrial function (respirometry 
studies).  
This work identifies new mitochondrial targets of Bendavia: MCU, MCUR1 and different 
MRCs as well as their supramolecular organizations, respirasomes. Whether Bendavia acts 
directly or indirectly on these targets remains to be determined. However, the overall improved 
mitochondrial function and the preservation of multiple proteins of the inner mitochondrial 
membrane could, potentially, be explained by the action of Bendavia on a common denominator 
to all this targets. A potential common denominator that is important for the structure and 
function of multiple respiratory complexes as well as the respirasomes is cardiolipin. This idea of 
Bendavia targeting cardiolipin is supported by the newly proposed interaction between 
cardiolipin and Bendavia [44]. Further studies are warranted to unravel the interaction between 
Bendavia and cardiolipin in diabetic and ischemic hearts.  
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Taken together, the results presented herein provide new insight into the molecular and 
functional alterations that occur along the mitochondrial inner membrane in diabetic and post-
ischemic hearts. These data provide a basis for novel therapies targeting the inner mitochondrial 
membrane as viable pharmacological approaches to improving bioenergetics in diseased 
myocardium.   
Limitations 
One limitation to our studies (presented in chapters 2 and 3) is the use of STZ-induced 
diabetes model which mimics more closely Type I diabetes. However, this model presents 
multiple pathological characteristics in common with Type II diabetes in both humans and 
animal models. Hearts from STZ-induced diabetic rats display alterations in myocardial calcium 
handling, substrate utilization, mitochondrial energetics, and enhanced oxidative stress (recently 
reviewed in [19]). So for the pathological aspects investigated in this work STZ model of 
diabetes was adequate. Another limitation is that we did not directly link mitochondrial Ca 
uptake to the energy supply-demand mismatching in whole hearts. Although we have tried to do 
so using spermine to activate MCU and see whether we could improve myocardial oxygen 
consumption in diabetic hearts, we obtained inconsistent results and decided to not pursue that 
approach.   
Future directions 
In chapter 3, we showed an association between reduced levels of MCU, MCUR1 and 
energy-supply demand mismatching in diabetic hearts. Future experiments are necessary to 
establish a causative relationship between MCU/MCUR1 and the energy supply-demand 
mismatching. For MCU, this can be easily accomplished using MCU-knockout mice and looking 
at their ability to match energy supply to demand with increasing cardiac workload. The activity 
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of Ca-sensitive dehydrogenases can also be examined and related to oxidative phosphorylation 
and ATP synthesis.  
In chapter 4, we showed that supercomplexes content was reduced in post-ischemic 
hearts and was brought back to control levels when the hearts were treated with Bendavia at 
reperfusion. Future studies should determine whether these molecular changes translate into 
functional changes as well. Since the supercomplexes are in their native states, we can measure 
their enzymatic activities as well as their respiratory capacity.  
Future studies are also needed to analyze the supercomplexes bands in order to 
determine: 1) the nature and stoichiometry of the respiratory complexes (I, II, III2 or IV1-4) and 2) 
the content and nature of cardiolipin in these supercomplexes. The results of these studies will 
allow us to determine whether the decrease in the content of supercomplexes is due to the 
dissociation of specific respiratory complexes (as we think is happening for complex I since the 
free form is increased) or it is due to a non-optimal assembly because of loss of cardiolipin.
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